<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN"  "JATS-archivearticle1-mathml3.dtd"><article article-type="research-article" dtd-version="1.2" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn pub-type="epub" publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">73753</article-id><article-id pub-id-type="doi">10.7554/eLife.73753</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Neuroscience</subject></subj-group></article-categories><title-group><article-title>Glial Nrf2 signaling mediates the neuroprotection exerted by <italic>Gastrodia elata</italic> Blume in Lrrk2-G2019S Parkinson’s disease</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-253493"><name><surname>Lin</surname><given-names>Yu-En</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-5848-5405</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-253494"><name><surname>Lin</surname><given-names>Chin-Hsien</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-8566-7573</contrib-id><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-253495"><name><surname>Ho</surname><given-names>En-Peng</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-253496"><name><surname>Ke</surname><given-names>Yi-Ci</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-253497"><name><surname>Petridi</surname><given-names>Stavroula</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="other" rid="fund2"/><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-253498"><name><surname>Elliott</surname><given-names>Christopher JH</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="other" rid="fund2"/><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" corresp="yes" id="author-253499"><name><surname>Sheen</surname><given-names>Lee-Yan</given-names></name><email>lysheen@ntu.edu.tw</email><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" corresp="yes" id="author-14952"><name><surname>Chien</surname><given-names>Cheng-Ting</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-7906-7173</contrib-id><email>ctchien@gate.sinica.edu.tw</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution>Institute of Molecular Biology, Academia Sinica</institution><addr-line><named-content content-type="city">Taipei</named-content></addr-line><country>Taiwan</country></aff><aff id="aff2"><label>2</label><institution>Institute of Food Science and Technology, National Taiwan University</institution><addr-line><named-content content-type="city">Taipei</named-content></addr-line><country>Taiwan</country></aff><aff id="aff3"><label>3</label><institution>Department of Neurology, National Taiwan University Hospital</institution><addr-line><named-content content-type="city">Taipei</named-content></addr-line><country>Taiwan</country></aff><aff id="aff4"><label>4</label><institution>Department of Clinical Neurosciences and MRC Mitochondrial Biology Unit, University of Cambridge</institution><addr-line><named-content content-type="city">Cambridge</named-content></addr-line><country>United Kingdom</country></aff><aff id="aff5"><label>5</label><institution>Department of Biology and York Biomedical Research Institute, University of York</institution><addr-line><named-content content-type="city">York</named-content></addr-line><country>United Kingdom</country></aff><aff id="aff6"><label>6</label><institution>Neuroscience Program of Academia Sinica, Academia Sinica</institution><addr-line><named-content content-type="city">Taipei</named-content></addr-line><country>Taiwan</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Bellen</surname><given-names>Hugo J</given-names></name><role>Reviewing Editor</role><aff><institution>Baylor College of Medicine</institution><country>United States</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Pfeffer</surname><given-names>Suzanne R</given-names></name><role>Senior Editor</role><aff><institution>Stanford University School of Medicine</institution><country>United States</country></aff></contrib></contrib-group><pub-date date-type="publication" publication-format="electronic"><day>15</day><month>11</month><year>2021</year></pub-date><pub-date pub-type="collection"><year>2021</year></pub-date><volume>10</volume><elocation-id>e73753</elocation-id><history><date date-type="received" iso-8601-date="2021-09-09"><day>09</day><month>09</month><year>2021</year></date><date date-type="accepted" iso-8601-date="2021-11-12"><day>12</day><month>11</month><year>2021</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint at bioRxiv.</event-desc><date date-type="preprint" iso-8601-date="2021-08-27"><day>27</day><month>08</month><year>2021</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2021.08.25.457612"/></event></pub-history><permissions><copyright-statement>© 2021, Lin et al</copyright-statement><copyright-year>2021</copyright-year><copyright-holder>Lin et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-73753-v2.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-73753-figures-v2.pdf"/><abstract><p>The most frequent missense mutations in familial Parkinson’s disease (PD) occur in the highly conserved <italic>LRRK2/PARK8</italic> gene with G2019S mutation. We previously established a fly model of PD carrying the <italic>LRRK2-G2019S</italic> mutation that exhibited the parkinsonism-like phenotypes. An herbal medicine<italic>, Gastrodia elata</italic> Blume (GE), has been reported to have neuroprotective effects in toxin-induced PD models. However, the underpinning molecular mechanisms of GE beneficiary to G2019S-induced PD remain unclear. Here, we show that these G2019S flies treated with water extracts of GE (WGE) and its bioactive compounds, gastrodin and 4-HBA, displayed locomotion improvement and dopaminergic neuron protection. WGE suppressed the accumulation and hyperactivation of G2019S proteins in dopaminergic neurons and activated the antioxidation and detoxification factor Nrf2 mostly in the astrocyte-like and ensheathing glia. Glial activation of Nrf2 antagonizes G2019S-induced Mad/Smad signaling. Moreover, we treated <italic>LRRK2-G2019S</italic> transgenic mice with WGE and found that the locomotion declines, the loss of dopaminergic neurons, and the number of hyperactive microglia were restored. WGE also suppressed the hyperactivation of G2019S proteins and regulated the Smad2/3 pathways in the mice brains. We conclude that WGE prevents locomotion defects and the neuronal loss induced by G2019S mutation via glial Nrf2/Mad signaling, unveiling a potential therapeutic avenue for PD.</p></abstract><abstract abstract-type="executive-summary"><title>eLife digest</title><p>Parkinson’s disease is a brain disorder that leads to tremors and difficulties with balance and coordination. These symptoms are caused by the loss of neurons which release a chemical messenger that is needed to regulate movement called dopamine. Most treatments for this disease work by boosting levels of dopamine in the brain, but this can lead to severe side effects and these drugs often become less effective over time.</p><p>A traditional Chinese medicine called <italic>Gastrodia elata</italic> Blume (or GE for short) has previously been reported to relieve symptoms of Parkinson’s disease in both human and animal studies when administered as a decoction or formula. However, it is unclear how GE protects dopamine-producing neurons and if this mechanism involves another type of brain cell known as glia that has also been linked to Parkinson’s disease.</p><p>To investigate, Lin et al. studied fruit flies and mice that carry a genetic mutation that produces the symptoms and molecular characteristics of Parkinson’s disease. The experiments showed that when the flies and mice were fed food containing water extracts of GE, they experienced less difficulties moving and had a higher number of intact dopamine-producing neurons.</p><p>Lin et al. found that GE switched on a protein in glial cells located near dopamine-producing neurons. Activation of this protein, called Nrf2, inhibited a signaling pathway in degenerating neurons that leads to the disease state. As a result, less dopamine-producing neurons were damaged and the animals’ coordination and balance were maintained.</p><p>These findings suggest that GE could potentially provide an alternative or complementary therapy for Parkinson’s disease, although it still needs to be studied further in humans. If the same effect is observed, the specific compounds in GE that have this protective effect could be isolated and analyzed to see if they could be used for treatment.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>Parkinson's disease</kwd><kwd>Lrrk2</kwd><kwd><italic>Gastrodia elata</italic> Blume</kwd><kwd>Nrf2</kwd><kwd>BMP/Mad</kwd><kwd>glia</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd><italic>D. melanogaster</italic></kwd><kwd>Mouse</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100004663</institution-id><institution>Ministry of Science and Technology, Taiwan</institution></institution-wrap></funding-source><award-id>MOST-108-2311-B-001-039-MY3</award-id><principal-award-recipient><name><surname>Chien</surname><given-names>Cheng-Ting</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000304</institution-id><institution>Parkinson's UK</institution></institution-wrap></funding-source><award-id>H1201</award-id><principal-award-recipient><name><surname>Petridi</surname><given-names>Stavroula</given-names></name><name><surname>Elliott</surname><given-names>Christopher JH</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>The traditional herbal medicine <italic>Gastrodia elata</italic> Blume, in the water-extracted form as food supplement, improves locomotion and protects dopaminergic neurons in Lrrk2-G2019S Parkinson’s disease models through Nrf2 activation in glia.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Parkinson’s disease (PD) is a highly prevalent neurodegenerative disorder characterized by the loss of dopaminergic neurons in the substantia nigra projecting to the striatum of the basal ganglion, representing a circuit involved in motor planning and coordination. As a consequence, PD is associated with motor abnormalities, bradykinesia, hypokinesia, rigidity, and resting tremor. Currently, the most frequently applied pharmacological treatment, levodopa (L-DOPA), exerts limited motor improvement and elicits negative side effects (<xref ref-type="bibr" rid="bib61">Ray Chaudhuri et al., 2018</xref>). Hence, identifying and developing alternative or complementary treatments may assist in mitigating PD progression.</p><p>PD is a multicausal disease with a complicated etiology, including familial inheritance. More than 20 <italic>PARK</italic> genes have been genetically linked to PD, a number that is increasing (<xref ref-type="bibr" rid="bib21">Houlden and Singleton, 2012</xref>). Missense mutations in <italic>PARK8</italic>, or <italic>Leucine-rich repeat kinase 2</italic> (<italic>LRRK2</italic>), induce characteristic PD symptoms and pathologies such as loss of dopaminergic neurons and the appearance of Lewy bodies (<xref ref-type="bibr" rid="bib51">Martin et al., 2014</xref>). Notably, the most commonly observed mutation, dominant G2019S, among familial PD cases is located in the kinase domain of Lrrk2, which augments its kinase activity via auto- and hyperactivation (<xref ref-type="bibr" rid="bib65">Sheng et al., 2012</xref>). The hyperactive G2019S mutant protein alters several cellular processes, including vesicle trafficking, microtubule dynamics, autophagy, mitochondrial function (<xref ref-type="bibr" rid="bib51">Martin et al., 2014</xref>), and, most commonly, increases susceptibility to oxidative stress that contributes to neuronal degeneration (<xref ref-type="bibr" rid="bib1">Angeles et al., 2011</xref>; <xref ref-type="bibr" rid="bib54">Nguyen et al., 2011</xref>). These indicate that regulation of the hyperactivation of G2019S mutant protein appears to be a disease-modifying strategy.</p><p>Glia provide structural and metabolic supports to neurons and regulate synaptic transmissions, so they are important for the function and survival of dopaminergic neurons (<xref ref-type="bibr" rid="bib37">Lin et al., 1993</xref>; <xref ref-type="bibr" rid="bib68">Sofroniew and Vinters, 2010</xref>). Dysfunction in two major glial types, astrocytes and microglia, contribute to the onset and progression of both sporadic and familial PD (<xref ref-type="bibr" rid="bib27">Kam et al., 2020</xref>). Astrocytes and microglia of postmortem PD brains exhibit pathological lesions and hyper-immunoactivity (<xref ref-type="bibr" rid="bib52">Miklossy et al., 2006</xref>). A clinical trial involving downregulation of microglial oxidative stress highlights the significance of glia to PD (<xref ref-type="bibr" rid="bib26">Jucaite et al., 2015</xref>). Moreover, Lrrk2 regulates the inflammatory response in microglia and the autophagy-lysosome pathway in astrocytes, with the G2019S mutation altering the size and pH of lysosomes (<xref ref-type="bibr" rid="bib19">Henry et al., 2015</xref>; <xref ref-type="bibr" rid="bib53">Moehle et al., 2012</xref>). Expression of G2019S mutant protein in neurons was previously shown to induce the secretion of Glass bottom boat (Gbb)/bone morphogenetic protein (BMP) signal that, in turn, upregulates Mothers against decapentaplegic (Mad)/Smad signaling in glia, which prompts feedback signals to promote neuronal degeneration (<xref ref-type="bibr" rid="bib49">Maksoud et al., 2019</xref>). These studies indicate that G2019S mutant protein alters the homeostasis and interaction between neurons and glia, contributing to PD pathogenesis. However, whether any dietary or pharmacological treatment blockading this neuron-glia interaction beneficiary to G2019S-induced PD is unclear.</p><p>Given that up to 70% of human <italic>PARK</italic> genes are conserved in the <italic>Drosophila</italic> genome, <italic>Drosophila</italic> is frequently used as a PD model for studying gene function, such as the <italic>PARK1/SNCA</italic> (<xref ref-type="bibr" rid="bib6">Chen and Feany, 2005</xref>) and <italic>PARK8/LRRK2</italic> (<xref ref-type="bibr" rid="bib46">Liu et al., 2008</xref>). Genetic and molecular linkage between <italic>PINK1/PARK6</italic> and <italic>Parkin/PARK2</italic> was first established in <italic>Drosophila</italic> (<xref ref-type="bibr" rid="bib13">Clark et al., 2006</xref>). When overexpressed in <italic>Drosophila</italic> dopaminergic neurons, <italic>LRRK2</italic> transgenes carrying G2019S or other dominant mutations induce dopaminergic neuron loss and locomotion impairment, two age-dependent symptoms of PD (<xref ref-type="bibr" rid="bib41">Lin et al., 2010</xref>; <xref ref-type="bibr" rid="bib46">Liu et al., 2008</xref>). The G2019S model has further been used to screen a collection of FDA-approved drugs to suppress these PD phenotypes. Thus, <italic>Drosophila</italic> represents an amenable model of PD for genetic, molecular, and pharmacological study of potential therapeutic interventions. Strikingly, lovastatin was found to prevent dendrite degeneration, dopaminergic neuron loss, and impaired locomotion, and, critically, a lovastatin-involved Nrf2 pathway proved neuroprotective (<xref ref-type="bibr" rid="bib42">Lin et al., 2016a</xref>). Nevertheless, whether the Nrf2-mediated neuroprotection is cell- or non-cell-autonomous remains elusive.</p><p>Traditional Chinese Medicine (TCM) is often used as an alternative or dietary treatment for human diseases, including PD (<xref ref-type="bibr" rid="bib29">Kim et al., 2012</xref>; <xref ref-type="bibr" rid="bib36">Li et al., 2017</xref>). Although the results were inconclusive, some TCM could display adjuvant effects when used in combination with L-DOPA, reducing the L-DOPA dosage required in long-term treatments and relieving non-motor symptoms (<xref ref-type="bibr" rid="bib29">Kim et al., 2012</xref>). As a prominent component in TCM, <italic>Gastrodia elata</italic> Blume (GE; Orchidaceae) has been used to treat neurological disorders for centuries (<xref ref-type="bibr" rid="bib7">Chen and Sheen, 2011</xref>). GE has been shown to exert neuroprotective, anti-inflammatory, and antioxidative effects in neurodegenerative disease models (<xref ref-type="bibr" rid="bib22">Jang et al., 2015</xref>). The major bioactive compounds in GE include gastrodin and 4-hydroxybenzyl alcohol (4-HBA), both of which display pharmacological effects on neurobiological and psychological disorders (<xref ref-type="bibr" rid="bib10">Chen et al., 2016</xref>; <xref ref-type="bibr" rid="bib33">Kumar et al., 2013</xref>). Additionally, gastrodin and 4-HBA have been reported to activate the Nrf2 signaling in dopaminergic neurons and astrocytes, respectively (<xref ref-type="bibr" rid="bib23">Jiang et al., 2014</xref>; <xref ref-type="bibr" rid="bib47">Luo et al., 2017</xref>), highlighting a potential benefit of incorporating GE in PD treatments. However, the effects and mechanisms underlying how GE moderate Lrrk2-G2019S PD remain unclear.</p><p>In the present study, we treated G2019S animals with water extract of GE (WGE), and its bioactive compounds, gastrodin and 4-HBA. We have investigated the impact of WGE treatment on PD in restoring locomotion and protecting dopaminergic neurons in the <italic>Drosophila</italic> G2019S model. We identified two distinct pathways induced by WGE in the model, that is, suppression of Lrrk2 protein accumulation and hyperphosphorylation in neurons, and activation of the Nrf2 pathway in glia, particularly in astrocyte-like and ensheathing glia. We show that WGE-induced Nrf2 activation antagonizes the Gbb-activated Mad signaling in glia, contributing to neuronal protection. WGE also suppressed the hyperactivation of G2019S proteins and antagonized Smad2/3 signaling in a <italic>LRRK2-G2019S</italic> mouse model, which restored locomotion, protected dopaminergic neurons, and regulated the microglia hyperactivation. Conservation of the pathways impacted by WGE treatment in both the <italic>Drosophila</italic> and mouse G2019S models implies the beneficial effects of GE and represent a reliable and effective complementary therapy for PD.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>WGE treatment improves locomotion of <italic>Ddc&gt;G2019S</italic> flies</title><p>We employed the <italic>GAL4-UAS</italic> system to express the human G2019S mutant of Lrrk2 by the <italic>Ddc-GAL4</italic> driver (<italic>Ddc&gt;G2019S</italic>) in dopaminergic neurons and then assessed the anti-geotactic climbing activity of adult flies. We observed that locomotion of <italic>Ddc&gt;G2019S</italic> flies was affected significantly relative to control flies expressing human wild-type Lrrk2 (<italic>Ddc&gt;Lrrk2</italic>) (<xref ref-type="fig" rid="fig1">Figure 1A</xref>, <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1A</xref>). At weeks 1 and 2, more than 80% of <italic>Ddc&gt;G2019S</italic> flies could successfully climb above an 8 cm threshold, a proportion comparable to that of <italic>Ddc&gt;Lrrk2</italic> flies. However, the success rate declined to ~40% at week 3, ~ 20% at week 4, and to less than 10% at weeks 5 and 6. These proportions are significantly lower than the ~80% at week 3, ~60% at week 4, and ~40% at weeks 5 and 6 displayed by <italic>Ddc&gt;Lrrk2</italic> flies. Although both <italic>Ddc&gt;G2019S</italic> and <italic>Ddc&gt;Lrrk2</italic> flies failed to reach the 8 cm mark at weeks 7 and 8, <italic>Ddc&gt;Lrrk2</italic> flies could still climb the wall, whereas almost all <italic>Ddc&gt;G2019S</italic> flies could not (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1A</xref>). We also tested the climbing activity of another control expressing GFP in dopaminergic neurons (<italic>Ddc&gt;mCD8-GFP</italic>). Both <italic>Ddc&gt;Lrrk2</italic> and <italic>Ddc&gt;mCD8-GFP</italic> flies showed comparable climbing activities in the first six weeks, and a significant number of <italic>Ddc&gt;mCD8-GFP</italic> flies were still able to climb above the 8 cm mark at week 7. Therefore, we used the <italic>Ddc&gt;Lrrk2</italic> line as a control for <italic>Ddc&gt;G2019S</italic> flies in subsequent experiments to dissect the specific mode of pathogenicity of the G2019S mutation.</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Water extract of <italic>Gastrodia elata</italic> Blume (WGE) treatment rescues the diminished locomotion of <italic>Ddc&gt;G2019S</italic> flies.</title><p>(<bold>A</bold>–<bold>C</bold>) Climbing activities of <italic>Ddc&gt;G2019S</italic> flies fed on food supplemented with 0.1, 0.5, or 1.0% WGE (<bold>A</bold>), 0.1 or 1.0 mM gastrodin (<bold>B</bold>), and 0.1 or 1.0 mM 4-hydroxybenzyl alcohol (4-HBA) (<bold>C</bold>). Controls are <italic>Ddc&gt;Lrrk2</italic> and <italic>Ddc&gt;G2019S</italic> flies fed regular food. Bar graphs show the percentages of flies (mean ± SEM, N = 6) that climbed above 8 cm within 10 s. (<bold>D</bold>) Five-minute walking tracks pooled from eight flies each of the <italic>Ddc&gt;Lrrk2</italic>, <italic>Ddc&gt;G2019S,</italic> and <italic>Ddc&gt;G2019S</italic> + 0.1% WGE groups at week 4. Bar graph at right summarizes their walking distances (mean ± SEM, N = 8). One-way analysis of variance (ANOVA) with Tukey’s post-hoc multiple comparison test: *p&lt;0.05, **p&lt;0.01, and ***p&lt;0.001, ns, not significant.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-73753-fig1-v2.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>Climbing activity assay of <italic>Ddc&gt;mCD8-GFP</italic> and <italic>Ddc&gt;Lrrk2</italic> flies.</title><p>(<bold>A</bold>) Comparable climbing activities were detected for <italic>Ddc&gt;mCD8-</italic>GFP and <italic>Ddc&gt;Lrrk2</italic> flies. Both exhibited better climbing activities than <italic>Ddc&gt;G2019S</italic> flies in the climbing assay from weeks 1 to 6. Bar graph shows percentage (mean ± SEM, N = 5) of flies that successfully climbed above 8 cm within 10 s. One-way analysis of variance (ANOVA) and Tukey’s post-hoc multiple comparison test: *p&lt;0.05, ***p&lt;0.001, ns, not significant. (<bold>B</bold>) <italic>Ddc&gt;G2019S</italic> flies fed with 0.02 or 0.1% water extract of <italic>Gastrodia elata</italic> Blume (WGE) exhibited improved climbing activity (mean ± SEM, N = 6). One-way ANOVA and Tukey’s post-hoc multiple comparison test: *p&lt;0.05, ***p&lt;0.001 (relative to <italic>Ddc&gt;G2019S</italic>); and <sup>##</sup>p&lt;0.01, <sup>###</sup>p&lt;0.001 (comparing different doses of WGE), ns, not significant.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-73753-fig1-figsupp1-v2.tif"/></fig><fig id="fig1s2" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 2.</label><caption><title>Locomotion improvement of <italic>Ddc&gt;G2019S</italic> flies starting water extract of <italic>Gastrodia elata</italic> Blume (WGE) feeding at week 4.</title><p>The climbing activities of <italic>Ddc&gt;Lrrk2</italic>, <italic>Ddc&gt;G2019S</italic>, and <italic>Ddc&gt;G2019S</italic> with 0.1% WGE feeding at week 4 were assessed at weeks 3–6. Bar graphs show success rates (mean ± SEM, N = 6) of flies climbing over 8 cm height in 10 s. One-way ANOVA and Tukey’s post-hoc multiple comparison test were performed and statistical significance is shown as ***p&lt;0.001, *p&lt;0.05, ns, not significant.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-73753-fig1-figsupp2-v2.tif"/></fig></fig-group><p>Next, we examined the effect of feeding flies with WGE as a dietary supplement at different concentrations (0.1, 0.5, or 1.0%, w/w). WGE treatment of <italic>Ddc&gt;G2019S</italic> flies at all three doses elicited a significant improvement in their climbing ability (<xref ref-type="fig" rid="fig1">Figure 1A</xref>). Strikingly, the lowest concentration (0.1%) of WGE proved the most effective, with <italic>Ddc&gt;G2019S</italic> flies still performing well at climbing (i.e., comparably to <italic>Ddc&gt;Lrrk2</italic> control flies) in weeks 5 and 6. The higher doses of WGE (0.5 and 1.0%) still exerted beneficial effects at weeks 3 and 4, albeit not as significantly as the 0.1% dose, but had no beneficial effect in weeks 5 and 6. As 0.1% is the lowest among the three doses tested, we lowered the dose of WGE to 0.02% and found that 0.02% WGE was less effective than 0.1% starting at week 3 till week 6, suggesting that 0.1% is the optimal dose in restoring the climbing activity of <italic>Ddc&gt;G2019S</italic> flies (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1B</xref>). We also tested the WGE effect on the <italic>Ddc&gt;G2019S</italic> flies that were fed with regular food without WGE for 3 weeks. At week 4, these <italic>Ddc&gt;G2019S</italic> flies also showed a significant improvement in their climbing ability compared to the age-matched <italic>Ddc&gt;G2019S</italic> flies fed continuously on regular food (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2</xref>). The effect of improving climbing activity in the WGE-fed <italic>Ddc&gt;G2019S</italic> flies was reduced at week 5 and diminished at week 6, suggesting that WGE feeding starting at earlier stages is important for long-term locomotion improvement.</p><p>Gastrodin and 4-HBA are two major phenolic compounds in GE displaying neuropharmacological effects (<xref ref-type="bibr" rid="bib79">Zhan et al., 2016</xref>). Feeding <italic>Ddc</italic>&gt;<italic>G2019S</italic> flies with food containing gastrodin (0.1 mM) equivalent to the amount in 0.1% WGE also restored locomotion of <italic>Ddc</italic>&gt;<italic>G2019S</italic> flies in weeks 2–4, though its impact diminished to nonsignificant levels at weeks 5 and 6. However, increasing the gastrodin dose 10-fold (1.0 mM) resulted in improved climbing activity at weeks 5 and 6 (<xref ref-type="fig" rid="fig1">Figure 1B</xref>). Similarly, the equivalent 0.1 mM of 4-HBA, the aglyconic form of gastrodin and the bioactive form in the brain (<xref ref-type="bibr" rid="bib78">Wu et al., 2017</xref>), was sufficient to restore the climbing ability of <italic>Ddc&gt;G2019S</italic> flies, and a 10-fold dose at 1.0 mM had an even better effect (<xref ref-type="fig" rid="fig1">Figure 1C</xref>). These results indicate that both gastrodin and 4-HBA are primary bioactive compounds in GE that prevent locomotion decline in <italic>Ddc&gt;G2019S</italic> flies, and higher doses are more beneficial to reach the effect as WGE did.</p><p>Success in the antigravity wall-climbing assay also requires an immediate response to startle knockdown. Accordingly, we performed a second assay, free-walking in an open arena, to assess improved locomotion. Consistently, free-walking by <italic>Ddc&gt;G2019S</italic> flies was greatly impaired, with total walking distance reduced to less than 20% that displayed by control <italic>Ddc&gt;Lrrk2</italic> flies (<xref ref-type="fig" rid="fig1">Figure 1D</xref>). Moreover, <italic>Ddc&gt;G2019S</italic> flies displayed centrophobism, that is, they avoided walking into the central open space. Strikingly, 0.1% WGE feeding greatly extended walking distance and suppressed the centrophobism of <italic>Ddc&gt;G2019S</italic> flies. Together, these two assays strongly indicate that the defective locomotion exhibited by <italic>Ddc&gt;G2019S</italic> flies is greatly improved by feeding them with 0.1% WGE. Because the improvement on the locomotion was more effective in flies fed with 0.1% WGE than the pure compounds, we therefore fed the flies with 0.1% WGE in the following experiments.</p></sec><sec id="s2-2"><title>WGE treatment suppresses dopaminergic neuron loss in <italic>Ddc&gt;G2019S</italic> brain</title><p>Expression of G2019S mutant protein has been shown to induce a gradual loss of dopaminergic neurons in the adult fly brain, contributing to impaired locomotion (<xref ref-type="bibr" rid="bib41">Lin et al., 2010</xref>; <xref ref-type="bibr" rid="bib46">Liu et al., 2008</xref>). Several clusters of dopaminergic neurons have been identified in the adult brain of <italic>Drosophila</italic>. Here, we focused on the PPL1, PPL2, PPM1/2, and PPM3 clusters that have well-defined roles in modulating locomotion (<xref ref-type="bibr" rid="bib50">Mao and Davis, 2009</xref>) to assess the effect of WGE treatment. We detected reduced numbers of dopaminergic neurons in the PPL1, PPL2, PPM1/2, and PPM3 clusters of <italic>Ddc&gt;G2019S</italic> flies relative to <italic>Ddc&gt;Lrrk2</italic> controls, which increased in severity from weeks 2 to 6 (<xref ref-type="fig" rid="fig2">Figure 2</xref>, <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1A–C</xref>). Consistently, feeding <italic>Ddc&gt;G2019S</italic> flies with 0.1% WGE restored numbers of dopaminergic neurons in these clusters to the levels observed in controls (<xref ref-type="fig" rid="fig2">Figure 2</xref>, <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1A–C</xref>). Thus, concomitant rescue of locomotion and dopaminergic neuron populations in <italic>Ddc&gt;G2019S</italic> flies indicates that WGE treatment likely promotes dopaminergic neuron survival to restore locomotion.</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Water extract of <italic>Gastrodia elata</italic> Blume (WGE) prevents loss of dopaminergic neurons in <italic>Ddc&gt;G2019S</italic> flies.</title><p>(<bold>A</bold>) Representative adult brain images showing TH-positive dopaminergic neurons in the PPL1 cluster of 2-, 4-, and 6-week-old flies of the <italic>Ddc&gt;Lrrk2</italic>, <italic>Ddc&gt;G2019S</italic>, and 0.1% WGE-fed <italic>Ddc&gt;G2019S</italic> groups. Scale bar: 10 μm. (<bold>B</bold>) Average numbers (mean ± SEM, N = 5) of TH-positive dopaminergic neurons in the PPL1, PPM1/2, PPL2, and PPL3 clusters per brain hemisphere. One-way ANOVA with Tukey’s post-hoc multiple comparison test: *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001, ns, not significant.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-73753-fig2-v2.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>Water extract of <italic>Gastrodia elata</italic> Blume (WGE) treatment prevents dopaminergic neuron loss in <italic>Ddc&gt;G2019S</italic> flies.</title><p>(<bold>A–C</bold>) Representative adult whole-brain images for TH staining to reveal dopaminergic neurons in the PPL1, PPL2, PPM1/2, and PPM3 clusters of 2-, 4-, and 6-week-old flies. Scale bar: 40 μm. The images for the PPL1 cluster are shown as enhanced views of the dashed boxes in <xref ref-type="fig" rid="fig2">Figure 2</xref>.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-73753-fig2-figsupp1-v2.tif"/></fig></fig-group></sec><sec id="s2-3"><title>WGE treatment suppresses G2019S-induced Lrrk2 hyperactivation</title><p>The enhanced survival of dopaminergic neurons due to WGE treatment implies that WGE induces neuroprotective mechanisms in <italic>Ddc&gt;G2019S</italic> flies. The G2019S mutation causes Lrrk2 hyperphosphorylation, protein accumulation, and aberrant cellular signaling (<xref ref-type="bibr" rid="bib60">Price et al., 2018</xref>). Therefore, we explored if WGE-induced neuroprotection is responsible for abrogating these processes in G2019S flies. We detected comparable levels of Lrrk2 proteins in 3-day-old adult brains pan-neuronally expressing wild-type Lrrk2 (<italic>elav&gt;Lrrk2</italic>) or G2019S mutant protein (<italic>elav&gt;G2019S</italic>) (<xref ref-type="fig" rid="fig3">Figure 3A</xref>). However, phosphorylation levels at the Ser<sup>1292</sup> autophosphorylation site were higher in the <italic>elav&gt;G2019S</italic> flies compared to <italic>elav&gt;Lrrk2</italic> (<xref ref-type="fig" rid="fig3">Figure 3A and B</xref>). This outcome was also observed at week 4 (<xref ref-type="fig" rid="fig3">Figure 3F and G</xref>), consistent with the idea that Lrrk2 is hyperactivated upon G2019S mutation. Hyperphosphorylation in <italic>elav&gt;G2019S</italic> flies led to Lrrk2 protein accumulation, as determined by total Lrrk2 levels at weeks 2 and 4 (<xref ref-type="fig" rid="fig3">Figure 3D and E</xref>). However, both hyperphosphorylation and protein accumulation were suppressed upon feeding <italic>elav&gt;G2019S</italic> flies with 0.1% WGE (<xref ref-type="fig" rid="fig3">Figure 3D–G</xref>). In the <italic>elav&gt;Lrrk2</italic> control, WGE feeding had no effect on levels of wild-type Lrrk2 or Ser<sup>1292</sup> phosphorylation (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1A–C</xref>). We further examined the G2019S mutant-activated downstream effector Rab10, the phosphorylation status of which can serve as an indicator of Lrrk2 kinase activity (<xref ref-type="bibr" rid="bib28">Karayel et al., 2020</xref>). We observed that levels of phosphorylated Rab10 were increased in <italic>elav&gt;G2019S</italic> flies, but this phenotype was suppressed by WGE feeding (<xref ref-type="fig" rid="fig3">Figure 3F and H</xref>). Hence, feeding flies with WGE suppresses G2019S-induced Lrrk2 protein phosphorylation, accumulation, and signaling.</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Water extract of <italic>Gastrodia elata</italic> Blume (WGE) modulates Lrrk2 accumulation and hyperactivation in <italic>elav&gt;G2019S</italic> flies.</title><p>(<bold>A</bold>) Representative immunoblots of 3-day-old adult brain lysates showing expression levels of Lrrk2, pLrrk2 (phosphorylated at Ser<sup>1292</sup>), Akt, and pAkt (phosphorylated at Ser<sup>505</sup>) in <italic>elav&gt;Lrrk2</italic> and <italic>elav&gt;G2019S</italic> flies. (<bold>B, C</bold>) Quantifications (mean ± SEM, N = 3) of Lrrk2 and pLrrk2/Lrrk2 (<bold>B</bold>), and Akt and pAkt/Akt (<bold>C</bold>). (<bold>D</bold>) Representative immunoblots of 2- and 4-week-old adult brain lysates showing Lrrk2 levels in the fly groups <italic>elav&gt;Lrrk2</italic>, <italic>elav&gt;G2019S</italic>, and <italic>elav&gt;G2019S</italic> fed with 0.1% WGE. (<bold>E</bold>) Quantification of Lrrk2 levels in 2- and 4-week-old adult brains (mean ± SEM, N = 3). (<bold>F</bold>) Representative immunoblots of 4-week-old adult brain lysates showing expression levels of Lrrk2, pLrrk2, Rab10, and pRab10 (phosphorylated at Thr<sup>73</sup>). (<bold>G, H</bold>) Quantification (mean ± SEM, N = 3) of levels of Lrrk2 and pLrrk2/Lrrk2 (<bold>G</bold>), and of Rab10 and pRab10/Rab10 (<bold>H</bold>). One-way ANOVA with Tukey’s post-hoc multiple comparison test: *p&lt;0.05, **p&lt;0.01, ns, not significant.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-73753-fig3-v2.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title>Water extract of <italic>Gastrodia elata</italic> Blume (WGE) specifically modulates Lrrk2 accumulation and hyperactivation in <italic>elav&gt;G2019S</italic> but not <italic>elav&gt; Lrrk2</italic> flies.</title><p>(<bold>A</bold>) Representative immunoblots of 2-week-old adult brain lysates showing levels of Lrrk2 and pLrrk2 (Ser<sup>1292</sup>) in <italic>elav&gt;Lrrk2</italic>, WGE-fed <italic>elav&gt;Lrrk2, elav&gt;G2019S,</italic> and WGE-fed <italic>elav&gt;G2019S</italic> flies. (<bold>B, C</bold>) Quantification (mean ± SEM, N = 3) of Lrrk2 (<bold>B</bold>) and pLrrk2/Lrrk2 (<bold>C</bold>) levels. One-way ANOVA and Tukey’s post-hoc multiple comparison test: *p&lt;0.05, ***p&lt;0.001, ns, not significant.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-73753-fig3-figsupp1-v2.tif"/></fig></fig-group></sec><sec id="s2-4"><title>WGE treatment restores Akt/GSK3β/Nrf2 pathway activity</title><p>The Akt/GSK3β/Nrf2 signaling axis has been shown to promote survival of dopaminergic neurons and ameliorate motor dysfunction in PD models (<xref ref-type="bibr" rid="bib43">Lin et al., 2016b</xref>). We assayed the phosphorylation status of Akt at Ser<sup>505</sup> in 3-day-old adult fly head extracts and found reduced levels of pAkt in <italic>elav&gt;G2019S</italic> flies relative to <italic>elav&gt;Lrrk2</italic> controls (<xref ref-type="fig" rid="fig3">Figure 3A and C</xref>). This pAkt reduction persisted at weeks 2 and 4, but was abrogated by feeding <italic>elav&gt;G2019S</italic> flies with 0.1% WGE (<xref ref-type="fig" rid="fig4">Figure 4A and B</xref>). We also examined phosphorylation levels of Nrf2 at Ser<sup>40</sup> and GSK3β at Ser<sup>9</sup>, both of which were reduced upon expression of G2019S mutant protein and were equally offset by WGE feeding (<xref ref-type="fig" rid="fig4">Figure 4C and D</xref>). Induction of Akt/GSK3β/Nrf2 signaling activates expression of heme oxygenase 1 (HO-1), and we observed diminished levels of this latter protein in <italic>elav&gt;G2019S</italic> flies<italic>,</italic> which could be rescued by WGE feeding (<xref ref-type="fig" rid="fig4">Figure 4C and D</xref>). Therefore, WGE feeding restores the Akt/GSK3β/Nrf2 signaling activity compromised by the G2019S mutation.</p><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>Water extract of <italic>Gastrodia elata</italic> Blume (WGE) activates the Akt-Nrf2 pathway in <italic>elav&gt;G2019S</italic> flies.</title><p>(<bold>A</bold>) Representative immunoblots of 2- and 4-week-old adult brain lysates showing levels of Akt and pAkt in brain extracts of <italic>elav&gt;Lrrk2</italic>, <italic>elav&gt;G2019S</italic>, and WGE-fed <italic>elav&gt;G2019S</italic> flies. (<bold>B</bold>) Quantification (mean ± SEM, N = 3) of pAkt/Akt levels in 2- and 4-week-old adult brains. (<bold>C</bold>) Representative immunoblots of 4-week-old adult brain lysates showing levels of Nrf2, pNrf2 (phosphorylated at Ser<sup>40</sup>), GSK3β, pGSK3β (phosphorylated at Ser<sup>9</sup>), and HO-1 in <italic>elav&gt;Lrrk2</italic>, <italic>elav&gt;G2019S</italic>, and WGE-fed <italic>elav&gt;G2019S</italic> flies. GADPH acted as a loading control in (<bold>A</bold>) and (<bold>C</bold>). (<bold>D</bold>) Quantification (mean ± SEM, N = 3) of relative protein levels to respective Nrf2, GSK3β, and HO-1. One-way ANOVA with Tukey’s post-hoc multiple comparison test (relative to <italic>elav&gt;G2019S</italic>): *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001, ns, not significant.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-73753-fig4-v2.tif"/></fig></sec><sec id="s2-5"><title>Glial Nrf2 mediates the beneficial effect of WGE on restored locomotion and neuronal protection in G2019S flies</title><p>Restoration of Akt/GSK3β/Nrf2 signaling activity by WGE treatment prompted us to test by genetic assays if that signaling pathway mediates the WGE mode of action. We focused on the downstream effector Nrf2 encoded by <italic>cap-n-collar</italic> (<italic>cnc</italic>) in <italic>Drosophila</italic>. Intriguingly, neither overexpression (<italic>UAS-cncC-FL2</italic>) nor RNAi knockdown (<italic>UAS-cncTRiP</italic>) of Nrf2 in dopaminergic neurons had an impact on the climbing ability of <italic>Ddc&gt;G2019S</italic> flies (<xref ref-type="fig" rid="fig5">Figure 5A</xref>). Also, WGE feeding still rescued locomotion of <italic>Ddc&gt;G2019S</italic> flies with Nrf2 knockdown (<italic>Ddc&gt;G2019S; cncTRiP</italic>) to levels comparable to WGE-fed control flies (<italic>Ddc&gt;G2019S; mCD8-GFP</italic>) without Nrf2 knockdown (<xref ref-type="fig" rid="fig5">Figure 5A</xref>). Thus, the Nrf2 pathway activation by WGE that appears to be effective in protecting neurons and restoring locomotion is likely exerted in cells other than neurons.</p><fig-group><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>Activation of Nrf2 in glia rescues locomotion defects in <italic>Ddc&gt;G2019S</italic> flies.</title><p>(<bold>A, B</bold>) Requirement of Nrf2 in glia but not neurons for water extract of <italic>Gastrodia elata</italic> Blume (WGE)-improved <italic>Ddc&gt;G2019S</italic> climbing activity. (<bold>A</bold>) Climbing success rates of flies in which <italic>Ddc-GAL4</italic> drives coexpression of <italic>Lrrk2-G2019S</italic> and <italic>mCD8-GFP</italic>, <italic>cncC-FL2</italic> or <italic>cnc-RNAi</italic>. As a control line, <italic>Ddc-GAL4</italic> drives coexpression of <italic>Lrrk2</italic> and <italic>mCD8-GFP</italic>. (<bold>B</bold>) Climbing success rates of flies in which <italic>Ddc-LexA</italic> drives wild-type <italic>Lrrk2</italic> or <italic>Lrrk2-G2019S</italic> expression and <italic>repo-GAL4</italic> drives <italic>cncC-FL2</italic> or <italic>cnc-RNAi</italic> expression (mean ± SEM, N = 6 for <bold>A</bold> and <bold>B</bold>). WGE was added to food at a concentration of 0.1% (w/w). (<bold>C</bold>) Adult brain images showing TH-positive dopaminergic neurons in the PPL1 clusters of 6-week-old <italic>Ddc-LexA&gt;Lrrk2</italic> or <italic>Ddc-LexA&gt;G2019S</italic> flies with <italic>repo-GAL4</italic> control or <italic>repo-GAL4</italic>-driven <italic>cncC-FL2</italic> or <italic>cnc-RNAi</italic> expression. Scale bar: 10 μm. (<bold>D</bold>) Average numbers (mean ± SEM, N = 5) of TH-positive dopaminergic neurons in PPL1 clusters per brain hemisphere are shown. One-way ANOVA with Tukey’s post-hoc multiple comparison test (relative to <italic>Ddc&gt;G2019S</italic> [<bold>A]</bold> or <italic>Ddc-LexA&gt;G2019S; repo-GAL4</italic> [<bold>B, D]</bold>): **p&lt;0.01, ***p&lt;0.001, ns, not significant.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-73753-fig5-v2.tif"/></fig><fig id="fig5s1" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 1.</label><caption><title>Water extract of <italic>Gastrodia elata</italic> Blume (WGE) treatment specifically activates glial Nrf2 signals in the <italic>ARE-GFP</italic> reporter flies.</title><p>(<bold>A, B</bold>) WGE treatment activates glial Nrf2 signals in 1-week-old <italic>ARE-GFP</italic> reporter flies. ARE-GFP (green) and glial Repo (red) in whole-mount adult brains without (<bold>A</bold>) or with 0.1% WGE treatment (<bold>B</bold>) for 5 days. Phalloidin (in blue) reveals brain structures. White arrowheads indicate GFP signals. Scale bar: 50 μm. Dotted boxes are enhanced views and shown as separate channels at right.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-73753-fig5-figsupp1-v2.tif"/></fig><fig id="fig5s2" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 2.</label><caption><title>Water extract of <italic>Gastrodia elata</italic> Blume (WGE) rescues the locomotion defect displayed by <italic>Ddc-LexA&gt;G2019S</italic> flies.</title><p>WGE treatment improves the climbing ability of <italic>Ddc-LexA&gt;G2019S</italic> flies. Bar graph shows percentage (mean ± SEM, N = 6) of flies that successfully climbed above 8 cm within 10 s. One-way ANOVA and Tukey’s post-hoc multiple comparison test (relative to <italic>Ddc-LexA&gt;G2019S</italic>): *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-73753-fig5-figsupp2-v2.tif"/></fig></fig-group><p>Nrf2 activation may be examined by assessing GFP signal from the <italic>ARE-GFP</italic> reporter that harbors Nrf2 binding sites and responds to Nrf2 activation (<xref ref-type="bibr" rid="bib5">Chatterjee and Bohmann, 2012</xref>). <italic>ARE-GFP</italic> adult fly brains displayed low basal GFP signals (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1A</xref>), but feeding with 0.1% WGE elicited many GFP-positive signals in Repo-positive glia (arrowheads in <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1B</xref>), evidencing that glia may be the primary cell type in which Nrf2 is activated.</p><p>Next, we investigated if WGE-induced Nrf2 activity in glia is effective in promoting locomotion in G2019S flies. To this end, we employed the <italic>LexA-LexAop</italic> system to overexpress wild-type Lrrk2 or G2019S mutant protein in dopaminergic neurons (<italic>Ddc-LexA&gt;Lrrk2</italic> and <italic>Ddc-LexA&gt;G2019S</italic>, respectively) and used the <italic>GAL4</italic> driver to manipulate Nrf2/CncC activity in glia (<italic>repo&gt;cncC-FL2</italic> for overexpression and <italic>repo&gt;cnc-RNAi</italic> for knockdown). As a first step, we validated the age-dependent locomotion decline of <italic>Ddc-LexA&gt;G2019S</italic> flies that was severer than <italic>Ddc-LexA&gt;Lrrk2</italic> and could be rescued by 0.1% WGE feeding (<xref ref-type="fig" rid="fig5s2">Figure 5—figure supplement 2</xref>). We then assayed the climbing ability of <italic>Ddc-LexA&gt;G2019S</italic> flies exhibiting <italic>repo-GAL4</italic>-driven Nrf2 overexpression in glia (<italic>Ddc-LexA&gt;G2019S; repo&gt;cncC-FL2</italic>). Significantly, the <italic>Ddc-LexA&gt;G2019S; repo&gt;cncC-FL2</italic> flies performed better in the climbing assay than <italic>Ddc-LexA&gt;G2019S; repo-GAL4</italic> without Nrf2 overexpression (<xref ref-type="fig" rid="fig5">Figure 5B</xref>). We also performed Nrf2 knockdown in glia (<italic>Ddc-LexA&gt;G2019S; repo&gt;cnc-RNAi</italic>), which had little impact on the already declined climbing activity in <italic>Ddc-LexA&gt;G2019S; repo-GAL4</italic> (<xref ref-type="fig" rid="fig5">Figure 5B</xref>). Importantly, WGE feeding could not rescue locomotion deficits of glial Nrf2-knockdown flies (<italic>Ddc-LexA&gt;G2019S; repo&gt;cnc-RNAi</italic>) (<xref ref-type="fig" rid="fig5">Figure 5B</xref>, compare to <italic>Ddc-LexA&gt;G2019S; repo-GAL4</italic> with WGE feeding). Thus, glial overexpression of Nrf2 partially restores locomotion of <italic>Ddc-LexA&gt;G2019S</italic> flies, and glial depletion of Nrf2 abolishes the ability of WGE to rescue impaired locomotion.</p><p>We stained dopaminergic neurons of 6-week-old adult fly brains and confirmed that numbers of TH-positive dopaminergic neurons in the PPL1 cluster were reduced in the <italic>Ddc-LexA&gt;G2019S; repo-GAL4</italic> flies compared to <italic>Ddc-LexA&gt;Lrrk2; repo-GAL4</italic> controls (<xref ref-type="fig" rid="fig5">Figure 5C and D</xref>). Importantly, numbers of dopaminergic neurons in the PPL1 cluster were restored upon glial overexpression of Nrf2 in the <italic>Ddc-LexA&gt;G2019</italic>S; <italic>repo&gt;cncC-FL2</italic> flies. In contrast, glial Nrf2 knockdown had little impact on the already reduced dopaminergic neurons. Taken together, these results support that glial Nrf2 is compromised in <italic>Ddc-LexA&gt;G2019S</italic> flies, and glial expression of Nrf2 protects the dopaminergic neurons.</p><p>Although WGE feeding suppressed hyperactivity of G2019S mutant protein (<xref ref-type="fig" rid="fig3">Figure 3D–G</xref>), it was not clear if WGE-mediated Nrf2 activation in glia could directly suppress mutant protein hyperactivity in dopaminergic neurons. To test this possibility, we compared the levels of total Lrrk2 protein and phosphorylated Lrrk2 protein in <italic>Ddc-LexA&gt;G2019S</italic> with and without glial Nrf2 overexpression (<italic>Ddc-LexA&gt;G2019S; repo-GAL4</italic> and <italic>Ddc-LexA&gt;G2019S; repo&gt;cncC</italic>). We observed comparable levels of Lrrk2 and pLrrk2 in the control and Nrf2 overexpression lines (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1A–C</xref>). Thus, the neuroprotective effects of Nrf2 activity are unlikely to operate through modulation of Lrrk2 levels or activity.</p></sec><sec id="s2-6"><title>Nrf2 in astrocyte-like and ensheathing glia is the major target of WGE</title><p>Five types of glia with different morphologies and functions have been identified in the fly brain (<xref ref-type="bibr" rid="bib16">Freeman, 2015</xref>). We decided to identify specific subtypes of glia that may mediate the WGE-induced Nrf2 activity endowing neuronal protection, given that dysfunctional astrocytes and microglia have been linked to onset and progression of both sporadic and familial PD (<xref ref-type="bibr" rid="bib27">Kam et al., 2020</xref>). In <italic>Ddc-LexA&gt;G2019S</italic> flies<italic>, GAL4</italic>-driven <italic>cnc</italic> knockdown in astrocyte-like (<italic>Ddc-LexA&gt;G2019S; alrm&gt;cnc-RNAi</italic>) or ensheathing glia (<italic>Ddc-LexA&gt;G2019S; R56F03&gt;cnc-RNAi</italic>) abolished the improved locomotion elicited by WGE treatment, recapitulating the effect of pan-glial Nrf2 knockdown (<italic>Ddc-LexA&gt;G2019S; repo&gt;cnc-RNAi</italic>) (<xref ref-type="fig" rid="fig6">Figure 6A</xref>). This outcome was not observed when we used GAL4 drivers to knock down <italic>cnc</italic> in cortex (<italic>np2222</italic>), perineurial (<italic>np6293</italic>), or subperineurial (<italic>moody</italic>) glia. We confirmed the involvement of astrocyte-like and ensheathing glia by means of Nrf2 overexpression in astrocyte-like (<italic>Ddc-LexA&gt;G2019S; alrm&gt;cncC-FL2</italic>) or ensheathing (<italic>Ddc-LexA&gt;G2019S; R56F03&gt;cncC-FL2</italic>) glia, with both treatments improving the climbing activity of <italic>Ddc-LexA&gt;G2019S</italic> flies not subjected to WGE feeding (<xref ref-type="fig" rid="fig6">Figure 6B</xref>). These analyses indicate that WGE feeding induces Nrf2 activity in astrocyte-like and ensheathing glia, which mitigates the reduced locomotion displayed by G2019S mutant-expressing flies.</p><fig-group><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>Nrf2 in astrocyte-like and ensheathing glia mediates the effect of water extract of <italic>Gastrodia elata</italic> Blume (WGE) treatment in <italic>Ddc&gt;G2019S</italic> flies.</title><p>(<bold>A</bold>) Nrf2 knockdown in astrocyte-like and ensheathing glia abolishes the improved locomotion elicited by WGE treatment in <italic>Ddc&gt;G2019S</italic> flies. Composite bar graph shows climbing success rates for 6-week-old <italic>Ddc-LexA&gt;G2019S</italic> flies with <italic>cnc-RNAi</italic> driven by <italic>repo-GAL4</italic> in all glia, <italic>alrm-GAL4</italic> in astrocyte-like glia, <italic>np2222</italic> in cortex glia, <italic>np6293</italic> in perineurial glia, <italic>R56F03</italic> in ensheathing glia, and <italic>moody-GAL4</italic> in subperineurial glia. (<bold>B</bold>) Composite bar graph shows climbing success rates (mean ± SEM, N = 6) for 6-week-old <italic>Ddc-LexA&gt;G2019S</italic> flies with overexpression of Nrf2 in astrocyte-like glia (<italic>alrm&gt;cncC-FL2</italic>) or ensheathing glia (<italic>R56F03&gt;cncC-FL2</italic>). One-way ANOVA and Tukey’s post-hoc multiple comparison test (relative to <italic>Ddc-LexA&gt;G2019S; GAL4&gt;cnc-RNAi</italic> [<bold>A]</bold> or <italic>Ddc-LexA&gt;G2019S; GAL4</italic> [<bold>B]</bold>): *p&lt;0.05, ***p&lt;0.001, ns, not significant. (<bold>C, E</bold>) Representative images showing expression of <italic>ARE-GFP</italic> in astrocyte-like glia (<italic>alrm&gt;mCherry</italic>) (<bold>C</bold>) and ensheathing glia (<italic>R56F03&gt;mCherry</italic>) (<bold>E</bold>), together with TH-positive dopaminergic neurons in the PPL1 clusters of 6-week-old <italic>Ddc-LexA&gt;Lrrk2</italic>, <italic>Ddc-LexA&gt;G2019S,</italic> or WGE (0.1% w/w)-fed <italic>Ddc-LexA&gt;G2019S</italic> flies. Bar: 5 μm. GFP channels in the dashed boxes are shown as enhanced views in the lower panel, with glial signals labeled by dashed lines. (<bold>D, F</bold>) Quantifications (mean ± SEM, n &gt; 25 for each genotype) of GFP intensities in astrocyte-like glia (<bold>D</bold>) or ensheathing glia (<bold>F</bold>). GFP intensities in glia have been outlined manually using the mCherry-positive signals. One-way ANOVA and Tukey’s post-hoc multiple comparison test (relative to <italic>Ddc-LexA&gt;G2019S; alrm&gt;mCherry</italic> [<bold>D]</bold> or <italic>Ddc-LexA&gt;G2019S; R56F03&gt;mCherry</italic> [<bold>F]</bold>): *p&lt;0.05, ***p&lt;0.001, ns, not significant.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-73753-fig6-v2.tif"/></fig><fig id="fig6s1" position="float" specific-use="child-fig"><label>Figure 6—figure supplement 1.</label><caption><title>Lrrk2 and pLrrk2 levels are maintained upon glial Nrf2 overexpression.</title><p>(<bold>A</bold>) Representative immunoblots of 2-week-old adult brain lysates showing protein expression levels of Lrrk2 and pLrrk2 (Ser<sup>1292</sup>) in <italic>Ddc-LexA&gt;G2019S; repo-GAL4</italic> and <italic>Ddc-LexA&gt;G2019S; repo&gt;cncC-FL2</italic> flies. (<bold>B, C</bold>) Quantification of Lrrk2 (<bold>B</bold>) and pLrrk2/Lrrk2 (<bold>C</bold>) (mean ± SEM, N = 3). Student <italic>t</italic>-test: ns, not significant.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-73753-fig6-figsupp1-v2.tif"/></fig><fig id="fig6s2" position="float" specific-use="child-fig"><label>Figure 6—figure supplement 2.</label><caption><title>Water extract of <italic>Gastrodia elata</italic> Blume (WGE) treatment induces a mild Nrf2 activation in dopaminergic neurons in <italic>Ddc&gt;G2019S</italic> flies.</title><p>(<bold>A, B</bold>) Quantifications (mean ± SEM, n &gt; 20 for each genotype) of GFP intensities in TH-positive dopaminergic neurons nearby the astrocyte-like glia (<bold>A</bold>) or ensheathing glia (<bold>B</bold>). GFP intensities were measured within dopaminergic neurons outlined by the TH-positive signals and were normalized to mCherry intensities. One-way ANOVA and Tukey’s post-hoc multiple comparison test with reference to <italic>Ddc-LexA&gt;G2019S; alrm&gt;mCherry</italic> (<bold>A</bold>) or <italic>Ddc-LexA&gt;G2019S; R56F03&gt;mCherry</italic> (<bold>B</bold>) were performed and shown as **p&lt;0.01, ***p&lt;0.001, ns, not significanct.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-73753-fig6-figsupp2-v2.tif"/></fig></fig-group><p>Next, we assayed Nrf2-regulated <italic>ARE-GFP</italic> expression in astrocyte-like and ensheathing glia of flies expressing G2019S mutant protein and subjected to WGE treatment. We focused on the astrocyte-like and ensheathing cells located adjacent to dopaminergic neurons. In control flies expressing wild-type Lrrk2, we detected basal levels of GFP signal in mCherry-positive astrocyte-like (<italic>alrm-GAL4</italic>) or ensheathing glia (<italic>R56F03</italic>) (<xref ref-type="fig" rid="fig6">Figure 6C–F</xref>). We detected lower levels of GFP signal in these cells when G2019S mutant protein was expressed in dopaminergic neurons. However, upon feeding with 0.1% WGE, we observed higher levels of GFP signal in both types of glia. Changes in the intensities of GFP signals were also detected in TH-positive dopaminergic neurons, although the levels were lower than in glia (<xref ref-type="fig" rid="fig6s2">Figure 6—figure supplement 2A and B</xref>). Thus, overexpression of G2019S mutant protein in dopaminergic neurons elicited reduced Nrf2 signaling activity, but WGE feeding restored or further enhanced Nrf2 activities in these two glial subtypes.</p></sec><sec id="s2-7"><title>Nrf2 activation antagonizes BMP signaling in glia</title><p>G2019S mutant protein in dopaminergic neurons has been shown previously to enhance the expression of the proprotein convertase Furin 1 (Fur1) that processes the BMP signaling molecule Gbb for maturation and release, leading to activation of the BMP signaling pathway in glia (<xref ref-type="bibr" rid="bib49">Maksoud et al., 2019</xref>). We confirmed that finding by removing one copy of <italic>Mad</italic> that encodes the pathway’s downstream effector to restore locomotion in <italic>Ddc&gt;G2019S</italic> flies (<xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1</xref>). To address if WGE-induced Nrf2 activation could antagonize BMP signaling activity in glia, first we assessed expression of the phosphorylated Mad (pMad) activated by BMP signaling. In glia of <italic>Ddc&gt;G2019S</italic> adult fly brains, pMad levels were higher than in <italic>Ddc&gt;Lrrk2</italic> brains and they could be suppressed by WGE treatment (<xref ref-type="fig" rid="fig7">Figure 7A and B</xref>). Similar to the previous report (<xref ref-type="bibr" rid="bib49">Maksoud et al., 2019</xref>), glial overexpression of Mad (<italic>UAS-Mad</italic>) or constitutively active type I receptor Tkv (<italic>UAS-tkv<sup>Q253D</sup></italic>) was sufficient to impair locomotion, even without expressing G2019S mutant protein in neurons. However, impaired locomotion was rescued in both cases by 0.1% WGE feeding (<xref ref-type="fig" rid="fig7">Figure 7C and D</xref>). In addition, numbers of dopaminergic neurons in the PPL1 cluster were reduced upon glial overexpression of <italic>Mad</italic> or <italic>tkv<sup>Q253D</sup></italic> and they were restored by 0.1% WGE treatment (<xref ref-type="fig" rid="fig7">Figure 7E–H</xref>). Together, these analyses indicate that activation of BMP signaling in glia recapitulates the phenotypes observed in flies overexpressing G2019S mutant protein in dopaminergic neurons and, furthermore, that these effects can be suppressed by WGE treatment.</p><fig-group><fig id="fig7" position="float"><label>Figure 7.</label><caption><title>Water extract of <italic>Gastrodia elata</italic> Blume (WGE) downregulates G2019S-induced BMP/Mad signaling.</title><p>(<bold>A</bold>) Representative images of glial pMad staining in the adult PPL1 clusters of <italic>Ddc&gt;Lrrk2</italic>, <italic>Ddc&gt;G2019S</italic>, and WGE-fed <italic>Ddc&gt;G2019S</italic> flies. White arrows indicate pMad signals co-localized with Repo, with single channels for pMad signals shown as insets. Bar: 10 μm. (<bold>B</bold>) Quantification (mean ± SEM, n &gt; 60 for each genotype) of pMad signals normalized to Repo levels in glia of the indicated genotypes. One-way ANOVA and Tukey’s post-hoc multiple comparison test (relative to <italic>Ddc&gt;G2019S</italic>): ***p&lt;0.001. (<bold>C, D</bold>) Climbing success rates (mean ± SEM, N = 10) at weeks 1–4 demonstrating that WGE treatment rescues locomotion deficits induced by glial overexpression of <italic>Mad</italic> (<bold>C</bold>) or <italic>tkv<sup>Q253D</sup></italic> (<bold>D</bold>) in <italic>Tub-GAL80<sup>ts</sup>; repo-GAL4</italic> flies. One-way ANOVA and Tukey’s post-hoc multiple comparison test (relative to <italic>repo&gt;Mad</italic> or <italic>repo&gt;tkvQ<sup>Q253D</sup></italic>): **p&lt;0.01, ***p&lt;0.001. (<bold>E, G</bold>) Representative images of 4-week-old adult brain showing TH staining of the PPL1 clusters of <italic>Tub-GAL80<sup>ts</sup>; repo-GAL4</italic>, <italic>Tub-GAL80<sup>ts</sup>; repo&gt;Mad</italic>, and WGE-fed <italic>Tub-GAL80<sup>ts</sup>; repo&gt;Mad</italic> flies (<bold>E</bold>), and <italic>Tub-GAL80<sup>ts</sup>; repo-GAL4</italic>, <italic>Tub-GAL80<sup>ts</sup>; repo&gt;tkvQ<sup>Q253D</sup></italic>, and WGE-fed <italic>Tub-GAL80<sup>ts</sup>; repo&gt;tkvQ<sup>Q253D</sup></italic> flies (<bold>G</bold>). Bars: 12.5 μm. (<bold>F, H</bold>) Bar graphs show mean ± SEM (N = 5) of TH-positive dopaminergic neurons in the PPL1 clusters of 4-week-old flies. One-way ANOVA and Tukey’s post-hoc multiple comparison test (relative to <italic>Tub-GAL80<sup>ts</sup>; repo&gt;Mad</italic> [<bold>F]</bold> or <italic>Tub-GAL80<sup>ts</sup>; repo&gt;tkvQ<sup>Q253D</sup></italic> [<bold>H]</bold>): ***p&lt;0.001.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-73753-fig7-v2.tif"/></fig><fig id="fig7s1" position="float" specific-use="child-fig"><label>Figure 7—figure supplement 1.</label><caption><title><italic>Mad</italic> heterozygosity rescues the impaired locomotion of <italic>Ddc&gt;G2019S</italic> flies.</title><p>Removing one copy of <italic>Mad</italic> improves <italic>Ddc&gt;G2019S</italic> climbing activity. Bar graphs show climbing success rates (mean ± SEM, N = 6) of 6-week-old <italic>Ddc&gt;Lrrk2, Ddc&gt;G2019S,</italic> and <italic>Ddc&gt;G2019S, Mad<sup>+/−</sup></italic> flies. One-way ANOVA and Tukey’s post-hoc multiple comparison test (relative to <italic>Ddc&gt;G2019S</italic>): ***p&lt;0.001.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-73753-fig7-figsupp1-v2.tif"/></fig></fig-group><p>Next, we explored if WGE-induced Nrf2 activation antagonizes BMP signaling in glia. Glial Nrf2 overexpression in <italic>Ddc-LexA&gt;G2019S</italic> flies (<italic>Ddc-LexA&gt;G2019S; repo&gt;cncC-FL2</italic>) partially rescued the locomotory impairment caused by G2019S mutation (<xref ref-type="fig" rid="fig5">Figure 5B</xref>), and removing one copy of <italic>Mad</italic> (<italic>Ddc-LexA&gt;G2019S, Mad<sup>+/-</sup>; repo&gt;cncC-FL2</italic>) further enhanced this effect (<xref ref-type="fig" rid="fig8">Figure 8A</xref>). Indeed, this outcome was equivalent to removing one copy of <italic>Mad</italic> but without Nrf2 overexpression (<italic>Ddc-LexA&gt;G2019S, Mad<sup>+/-</sup>; repo-GAL4</italic>), suggesting that Nrf2 functions mainly to antagonize Mad activity (<xref ref-type="fig" rid="fig8">Figure 8A</xref>). Consistently, Nrf2 overexpression in glia or WGE treatment suppressed the upregulation of pMad levels in glia caused by G2019S mutant protein overexpression in dopaminergic neurons (<italic>Ddc-LexA&gt;G2019S; repo-GAL4</italic>) (<xref ref-type="fig" rid="fig8">Figure 8B and C</xref>). Depletion of Nrf2 from glia (<italic>Ddc-LexA&gt;G2019S; repo&gt;cnc-RNAi</italic>), even in the presence of WGE treatment, maintained high pMad levels in glia (<xref ref-type="fig" rid="fig8">Figure 8B and C</xref>). Thus, modulation of Nrf2 activity, either by genetic manipulation or by WGE treatment, has an antagonistic effect on pMad levels in glia.</p><fig id="fig8" position="float"><label>Figure 8.</label><caption><title>Nrf2 antagonizes BMP/Mad signaling in glia.</title><p>(<bold>A</bold>) Heterozygosity of <italic>Mad</italic> suppresses G2019S mutation-induced locomotion impairment in a negative geotaxis assay. Bar graph shows percentages (mean ± SEM, N = 6) of 6-week-old flies that climbed above 8 cm within 10 s. One-way ANOVA and Tukey’s post-hoc multiple comparison test: *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001, ns, not significant. (<bold>B</bold>) Representative images of pMad staining in the adult brains of <italic>Ddc-LexA&gt;Lrrk2</italic> or <italic>Ddc-LexA&gt;G2019S</italic> flies in which <italic>repo-GAL4</italic> drives expression of <italic>cncC-FL2</italic> or <italic>cnc-RNAi</italic>. Impact of WGE treatment is shown in the rightmost panels. Arrows indicate pMad and Repo dual-positive cells. Insets are enlarged images of the dashed boxes, and dashed lines encompass Repo-positive cells. Bar: 20 μm. (<bold>C</bold>) Quantification of the ratio of pMad to Repo (mean ± SEM, N &gt; 40). One-way ANOVA and Tukey’s post-hoc multiple comparison test: ***p&lt;0.001, ns, not significant. (<bold>D</bold>) Images show pan-glial <italic>ARE-GFP</italic> expression (<italic>repo&gt;mCherry</italic>) in <italic>Ddc-LexA&gt;Lrrk2</italic>, <italic>Ddc-LexA&gt;G2019S</italic>, and <italic>Ddc-LexA&gt;G2019S</italic>, <italic>Mad</italic><sup>+/-</sup> fly brains. GFP channels within the dashed boxes are shown as enhanced views in the inset, with glial signals outlined by dashed lines. Bar: 20 μm. (<bold>E</bold>) Quantification for GFP expression levels (mean ± SEM, n &gt; 13). One-way ANOVA and Tukey’s post-hoc multiple comparison test: *p&lt;0.05, ***p&lt;0.001.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-73753-fig8-v2.tif"/></fig><p>We also addressed if <italic>Mad</italic> modulates expression of the Nrf2 target <italic>ARE-GFP</italic>. We observed diminished GFP signal in PPL1-surrounding glia of <italic>Ddc-LexA&gt;G2019S</italic> adult fly brains relative to the <italic>Ddc-LexA&gt;Lrrk2</italic> control. Heterozygosity of <italic>Mad</italic> in <italic>Ddc-LexA&gt;G2019S</italic> flies (<italic>Ddc-LexA&gt;G2019S, Mad<sup>+/-</sup></italic>) restored the level of GFP signal, implying that Mad modulates targeted gene expression induced by Nrf2 activity (<xref ref-type="fig" rid="fig8">Figure 8D and E</xref>).</p></sec><sec id="s2-8"><title>The effects of WGE treatment in a <italic>LRRK2-G2019S</italic> mouse model</title><p>To further study the effect of WGE on G2019S mutation-induced neurodegeneration in a mammalian system, we fed <italic>LRRK2-G2019S</italic> transgenic mice with WGE starting at the age of 8.5 months, that is, prior to onset of impairments in locomotion and dopaminergic neurons (<xref ref-type="bibr" rid="bib12">Chou et al., 2014</xref>). We quantified three locomotor activities from video-tracking paths of an open-field test, that is, accumulative moving distance, average velocity, and percentage of time moving (<xref ref-type="fig" rid="fig9">Figure 9A and B</xref>). At the age of 8.5 months, three groups—non-transgenic (nTg), transgenic <italic>LRRK2-G2019S</italic>, and WGE-fed transgenic <italic>LRRK2-G2019S</italic> mice—presented comparable locomotor activities. At 9.5 months of age, the <italic>LRRK2-G2019S</italic> mice displayed clearly impaired locomotion, which was statistically significant at the age of 11.5 months relative to nTg littermates (<xref ref-type="fig" rid="fig9">Figure 9B</xref>), consistent with a previous report (<xref ref-type="bibr" rid="bib8">Chen et al., 2012</xref>). Importantly, the <italic>LRRK2-G2019S</italic> mice fed with WGE showed improved locomotion throughout the 3-month treatment period, an outcome that was statistically significant at 11.5 months (<xref ref-type="fig" rid="fig9">Figure 9A and B</xref>). WGE treatment also suppressed the centrophobism displayed by <italic>LRRK2-G2019S</italic> mice (<xref ref-type="fig" rid="fig9">Figure 9A</xref>). We also analyzed the gait of these three groups of mice (<xref ref-type="fig" rid="fig9">Figure 9C</xref>). Similar to our findings from the open-field test, stride length of <italic>LRRK2-G2019S</italic> mice was significantly reduced at 11.5 months, but it was restored to the level of nTg mice by WGE feeding (<xref ref-type="fig" rid="fig9">Figure 9C and D</xref>). Collectively, these analyses show that WGE feeding is an effective means of restoring G2019S mutation-induced locomotory declines in this mouse model of PD.</p><fig id="fig9" position="float"><label>Figure 9.</label><caption><title>Water extract of <italic>Gastrodia elata</italic> Blume (WGE) treatment rescues impaired locomotion of <italic>LRRK2-G2019S</italic> mice.</title><p>(<bold>A</bold>) Video-tracked paths for nTg, <italic>LRRK2-G2019S,</italic> and WGE-fed <italic>LRRK2-G2019S</italic> mice (8.5 and 11.5 months old) during the open-field test. (<bold>B</bold>) Quantification of total distance (m), average velocity (cm/s), and percentage moving time for 8.5-, 9.5-, 10.5-, and 11.5-month-old mice. (<bold>C</bold>) Captured and converted images of single stance for each paw of 11.5-month-old nTg, <italic>LRRK2-G2019S,</italic> and WGE-fed <italic>LRRK2-G2019S</italic> mice in a catwalk analysis. (<bold>D</bold>) Quantification of stride length for each paw of 8.5- and 11.5-month-old mice. Data in (<bold>B) and (D</bold>) are presented as mean ± SEM (nTg; N = 5, <italic>G2019S</italic>; N = 6, WGE-fed <italic>G2019S</italic>; N = 6). One-way ANOVA and Tukey’s post-hoc multiple comparison test: *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001, ns, not significant. RF, right front; RH, right hind; LF, left front; LH, left hind.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-73753-fig9-v2.tif"/></fig><p>Since the nigral-striatal system contributes to locomotor function, we counted the number of TH-positive dopaminergic neurons in the substantia nigra. In comparison to nTg littermates, the number of dopaminergic neurons in 11.5-month-old <italic>LRRK2-G2019S</italic> mice was significantly reduced, but WGE treatment for 3 months abrogated this loss of dopaminergic neurons (<xref ref-type="fig" rid="fig10">Figure 10A and B</xref>). In the <italic>Ddc&gt;G2019S Drosophila</italic> model, glia mediate the protective effects of WGE on dopaminergic neurons. We found that activated microglia marked by ionized calcium-binding adapter molecule 1 (Iba-1) were increased in the substantia nigra of <italic>LRRK2-G2019S</italic> mice, but this increase was suppressed by WGE treatment (<xref ref-type="fig" rid="fig10">Figure 10C and D</xref>, <xref ref-type="fig" rid="fig10s1">Figure 10—figure supplement 1</xref>). We further analyzed levels of activated LRRK2 (pLRRK2) in lysates isolated from the nigra striatum. Levels of pLRRK2 normalized to LRRK2 signal were higher in <italic>LRRK2-G2019S</italic> mice than in nTg littermates, but WGE treatment partially abrogated that outcome (<xref ref-type="fig" rid="fig10">Figure 10E and F</xref>). Since G2019S mutation enhanced Mad signaling activation in the fly brain (<xref ref-type="fig" rid="fig8">Figure 8B and C</xref>), we also tested this scenario in the mouse model. Immunoblots revealed that the ratio of phosphorylated Smad2 to total Smad2 (pSmad2/Smad2) was significantly elevated in <italic>LRRK2-G2019S</italic> mice, but this increase was suppressed by WGE treatment (<xref ref-type="fig" rid="fig10">Figure 10E and G</xref>). Moreover, although the level of pSmad3/Smad3 was not significantly enhanced by G2019S mutant protein expression, it was suppressed by WGE treatment (<xref ref-type="fig" rid="fig10">Figure 10E and G</xref>). Thus, WGE feeding suppresses G2019S mutation-induced microglia activation and Smad signaling in the substantia nigra of the <italic>LRRK2-G2019S</italic> mouse model of PD.</p><fig-group><fig id="fig10" position="float"><label>Figure 10.</label><caption><title>Water extract of <italic>Gastrodia elata</italic> Blume (WGE) prevents dopaminergic neuron loss, microglial activation, and phosphorylation of LRRK2, Smad2, and Smad3.</title><p>(<bold>A, C</bold>) Representative images showing TH-positive dopaminergic neurons (<bold>A</bold>) or Iba-1-positive microglia (<bold>C</bold>) in the substantia nigra of 11.5-month-old nTg, <italic>LRRK2-G2019S,</italic> and WGE-fed <italic>LRRK2-G2019S</italic> mice. Bars: 100 μm in (<bold>A</bold>) and 50 μm in (<bold>C</bold>). (<bold>B, D</bold>) Quantification of numbers of TH-positive (<bold>B</bold>) or Iba-1-positive cells (<bold>D</bold>) relative to DAPI cells. (<bold>E</bold>) Representative immunoblots of nigrostriatal lysates prepared from 11.5-month-old nTg, <italic>LRRK2-G2019S,</italic> and WGE-fed <italic>LRRK2-G2019S</italic> mice reveal expression levels of LRRK2, pLRRK2 (Ser<sup>1292</sup>), Smad2, pSmad2 (Ser<sup>465</sup> and Ser<sup>467</sup>), Smad3, and pSmad3 (Ser<sup>423</sup> and Ser<sup>425</sup>). Actin acted as a loading control. (<bold>F, G</bold>) Quantifications of LRRK2 and pLRRK2/LRRK2 (<bold>F</bold>), as well as pSmad2/Smad2 and pSmad3/Smad3 (<bold>G</bold>). Data in (<bold>B, D, F, G</bold>) are presented as mean ± SEM (N = 3). One-way ANOVA and Tukey’s post-hoc multiple comparison test: *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001, ns, not significant.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-73753-fig10-v2.tif"/></fig><fig id="fig10s1" position="float" specific-use="child-fig"><label>Figure 10—figure supplement 1.</label><caption><title>Water extract of <italic>Gastrodia elata</italic> Blume (WGE) suppresses microglia activation in <italic>LRRK2-G2019S</italic> mice.</title><p>Single-channel images of <xref ref-type="fig" rid="fig10">Figure 10C</xref> show Iba-1-positive microglia in the substantia nigra of 11.5-month-old nTg, <italic>LRRK2-G2019S,</italic> and WGE-fed <italic>LRRK2-G2019S</italic> mice. Bars: 50 μm.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-73753-fig10-figsupp1-v2.tif"/></fig></fig-group><p>In summary, the potential mechanisms of WGE involved in the modulation of the neuron-glial interaction are proposed (<xref ref-type="fig" rid="fig11">Figure 11</xref>). WGE regulates the hyperactivation of G2019S mutant protein in dopaminergic neurons and antagonizes the Mad signaling by activating the Nrf2 pathway in glia. Both actions provide neuroprotection.</p><fig id="fig11" position="float"><label>Figure 11.</label><caption><title>The proposed model of water extract of <italic>Gastrodia elata</italic> Blume (WGE) in the G2019S-induced neurodegeneration.</title><p>Accumulation of the hyperactivated G2019S mutant protein enhances the BMP ligand (Gbb) maturation via upregulation of Furin 1 translation in dopaminergic neurons. Secreted Gbb binds to the BMP receptor, Tkv, and turns on Mad signaling in glia. The G2019S mutation also decreases the Nrf2 activity in the brain, particularly in glia. Both upregulated Mad and downregulated Nrf2 pathways contribute to neurodegeneration. WGE feeding suppresses G2019S hyperactivation in neurons and restores Nrf2 activity mostly in the astrocyte-like and ensheathing glia. WGE-elevated Nrf2 activity in glia antagonizes the BMP/Mad signaling and initiates Nrf2/HO-1 axis in glia, attenuating the stress signals from glia and promoting neuroprotection. Red and green solid arrows (→) indicate the observed effects exerted by G2019S overexpression and WGE feeding, respectively, in the present study. Red and green dashed arrows (--&gt;) indicate the proposed actions trigged by Mad signaling and WGE feeding, respectively. Red and green blunt-ended lines (---|) indicate the proposed inhibitions by Mad and Nrf2 overexpression, respectively. (P) Indicates phosphorylation. The Furin 1-mediated Gbb pathway labeled in gray is modified from Figure 6 of <xref ref-type="bibr" rid="bib49">Maksoud et al., 2019</xref>.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-73753-fig11-v2.tif"/></fig></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>Motor dysfunction in <italic>Drosophila</italic> neurodegeneration models has been frequently evaluated by means of negative-geotaxis assay that measures the insect innate response. The assay begins with a sudden external stimulation, which initially inhibits spontaneous locomotion but is followed by climbing behavior. The entire response requires motor circuit coordination and muscle tone regulation, two processes that progressively decline with age and that are impacted by neuropathological insults (<xref ref-type="bibr" rid="bib18">Grotewiel et al., 2005</xref>). In contrast, the open-arena walking assay allows free exploration without disturbance, representing an assay for locomotor activities that can reveal deficits like bradykinesia (<xref ref-type="bibr" rid="bib9">Chen et al., 2014</xref>). Our G2019S flies exhibited reduced locomotor activity in both assays. Moreover, the G2019S flies also exhibited centrophobism-like behavior in the open arena (<xref ref-type="fig" rid="fig1">Figure 1D</xref>). Centrophobism is indicative of emotional abnormalities, such as anxiety and depression, both of which are often associated with PD (<xref ref-type="bibr" rid="bib32">Kulisevsky et al., 2008</xref>), and was also displayed by the <italic>LRRK2-G2019S</italic> mice (<xref ref-type="fig" rid="fig9">Figure 9A</xref>). WGE treatment suppresses centrophobism in both fly and mouse PD models and has important implications for tackling major symptoms of PD and even non-PD-related depression, as reported for rodent models (<xref ref-type="bibr" rid="bib44">Lin et al., 2018</xref>; <xref ref-type="bibr" rid="bib43">Lin et al., 2016b</xref>). Thus, WGE treatment exerts beneficial effects in both of our PD models.</p><p>We found that the 0.1% dosage of WGE is optimal in suppressing age-dependent locomotion decline in G2019S flies, with higher and lower doses being less effective (<xref ref-type="fig" rid="fig1">Figure 1A</xref>, <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1B</xref>). Although an inverted U-shaped drug response is common, a plausible explanation for the diminished effectiveness of higher doses is that WGE downregulates the day-time but not night-time locomotor activity of flies (<xref ref-type="bibr" rid="bib25">Jo et al., 2017</xref>). In mice, higher WGE doses have sleep-promoting effects by activating adenosine A<sub>1</sub>/A<sub>2</sub>A receptors in the ventrolateral preoptic area (<xref ref-type="bibr" rid="bib80">Zhang et al., 2012</xref>). Thus, dosage level is critical to the beneficial effects of GE in both PD models.</p><p>Gastrodin and 4-HBA are considered the principal active components in GE (<xref ref-type="bibr" rid="bib79">Zhan et al., 2016</xref>). Although both compounds can cross the blood-brain barrier (<xref ref-type="bibr" rid="bib78">Wu et al., 2017</xref>), the capability of gastrodin to do so is relatively poor compared to aglyconic 4-HBA due to the glucose moiety (<xref ref-type="bibr" rid="bib39">Lin et al., 2007</xref>). Gastrodin is quickly metabolized to 4-HBA and undetermined metabolites in the brain (<xref ref-type="bibr" rid="bib40">Lin et al., 2008</xref>), perhaps explaining the lower effectiveness of gastrodin in G2019S flies. However, it is likely that the combination of gastrodin with other components in GE might exert optimal beneficial effects.</p><p>Expression of G2019S mutant protein impacts different clusters of dopaminergic neurons in the fly brain that are known for their connectivity and function. Activation of two specific mushroom body (MB)-projection dopaminergic neurons in the PPL1 cluster inhibits climbing performance (<xref ref-type="bibr" rid="bib71">Sun et al., 2018</xref>). Mutations in the circadian gene <italic>Clock</italic> (<italic>Clk</italic>) cause PPL1 dopaminergic neuron degeneration, accelerating impaired age-associated climbing ability (<xref ref-type="bibr" rid="bib75">Vaccaro et al., 2017</xref>). Dopaminergic neurons in the PPL2 cluster extend processes to the calyx of the MB, which has been linked to climbing activity (<xref ref-type="bibr" rid="bib71">Sun et al., 2018</xref>). In contrast, PPM3 neurons project to the central complex, activation of which enhances locomotion (<xref ref-type="bibr" rid="bib30">Kong et al., 2010</xref>). A significant reduction in dopaminergic neurons in the PPM1/2 cluster was only found at week 4 when impaired locomotion of G2019S flies was prominent. In a PD fly model involving <italic>SNCA</italic> overexpression and <italic>aux</italic> knockdown, dopaminergic neurons in the PPM1/2 cluster were selectively degenerated and this phenotype was accompanied by impaired locomotion in relatively young adult flies (<xref ref-type="bibr" rid="bib69">Song et al., 2017</xref>). We postulate that the age-dependent impaired locomotion displayed by G2019S flies could be caused by gradual and differential loss of dopaminergic neurons in these clusters, thereby affecting different aspects of locomotion. However, further study is needed to test that hypothesis.</p><p>Expression of the G2019S mutant protein induces Lrrk2 auto- and hyperphosphorylation, as well as protein accumulation, together enhancing cellular Lrrk2 activity and causing aberrant downstream signaling (<xref ref-type="bibr" rid="bib65">Sheng et al., 2012</xref>). We have shown here that neuronal expression of Lrrk2-G2019S reduced Akt phosphorylation (<xref ref-type="fig" rid="fig4">Figure 4A and B</xref>). Consistently, hyperactivated G2019S mutant protein impaired interaction with and phosphorylation of Akt, resulting in compromised signaling and accelerated neurodegeneration (<xref ref-type="bibr" rid="bib55">Ohta et al., 2011</xref>; <xref ref-type="bibr" rid="bib57">Panagiotakopoulou et al., 2020</xref>). However, WGE feeding restored downstream Akt signaling by suppressing G2019S mutant protein hyperactivation. Rab10, one of the best-characterized substrates for Lrrk2, mediates several of Lrrk2’s cellular functions (<xref ref-type="bibr" rid="bib28">Karayel et al., 2020</xref>). In <italic>Drosophila</italic>, Rab10 and Lrrk2-G2019S synergistically affect the activity of dopaminergic neurons, mediating deficits in movement (<xref ref-type="bibr" rid="bib15">Fellgett et al., 2021</xref>; <xref ref-type="bibr" rid="bib58">Petridi et al., 2020</xref>). We have shown that WGE treatment downregulated levels of Lrrk2 accumulation and phosphorylated Rab10 (<xref ref-type="fig" rid="fig3">Figure 3F–H</xref>), thus alleviating their synergistic toxicity. Several kinase inhibitors have been developed to block the kinase activity of Lrrk2, including of both wild-type Lrrk2 and the G2019S mutant, which could affect endogenous Lrrk2 activity (<xref ref-type="bibr" rid="bib65">Sheng et al., 2012</xref>). Instead, WGE treatment modulates the phosphorylation status and protein level of the G2019S mutant but not those of wild-type Lrrk2. The new hydrogen bond created at the Ser<sup>2019</sup> autophosphorylation site may provide a docking site for some chemicals in WGE, representing a possible explanatory mechanism that warrants further study (<xref ref-type="bibr" rid="bib34">Lang et al., 2015</xref>).</p><p>The antioxidation and detoxification factor Nrf2 is a target of Akt activation. Nrf2 phosphorylation and HO-1 expression levels revealed that Nrf2 is inactivated in G2019S flies, but it was activated by WGE treatment (<xref ref-type="fig" rid="fig4">Figure 4C and D</xref>). Intriguingly, our genetic data indicate that Nrf2 primarily functions in the glia of G2019S flies, with Nrf2 depletion from glia eliminating the beneficial effects of WGE and glial Nrf2 activation partially substituting for WGE feeding (<xref ref-type="fig" rid="fig5">Figure 5B</xref>). Cortical neurons express much lower levels of Nrf2 than astrocytes owing to hypo-acetylation and transcriptional repression of the <italic>Nrf2</italic> promoter (<xref ref-type="bibr" rid="bib4">Bell et al., 2015</xref>). Moreover, neurons express greater amounts of Cullin 3, the scaffold component of the E3 ubiquitin ligase that targets Nrf2 for proteasomal degradation (<xref ref-type="bibr" rid="bib24">Jimenez-Blasco et al., 2015</xref>). Both those mechanisms render neuronal Nrf2 inert to activation. Nrf2 activation in astrocytes maintains neuronal integrity and function against oxidative insults in response to stress by supplying antioxidants such as glutathione and HO-1 (<xref ref-type="bibr" rid="bib31">Kraft et al., 2004</xref>; <xref ref-type="bibr" rid="bib76">Vargas and Johnson, 2009</xref>). Previous study showed that 4-HBA triggers glia to secrete HO-1 via the Nrf2 pathway, protecting neurons from hydrogen peroxide in the primary culture (<xref ref-type="bibr" rid="bib47">Luo et al., 2017</xref>). In PD models in which wild-type or mutant α-synuclein is overexpressed, activation of neuronal Nrf2 (<xref ref-type="bibr" rid="bib3">Barone et al., 2011</xref>; <xref ref-type="bibr" rid="bib66">Skibinski et al., 2017</xref>) or astrocytic Nrf2 (<xref ref-type="bibr" rid="bib17">Gan et al., 2012</xref>) proved neuroprotective. In a previous study, lovastatin treatment provides neuroprotection in the G2019S-induced PD model, also through the Akt/Nrf2 pathway (<xref ref-type="bibr" rid="bib43">Lin et al., 2016b</xref>). As activation of neuronal Nrf2 plays a nonconventional role in promoting developmental dendrite pruning (<xref ref-type="bibr" rid="bib11">Chew et al., 2021</xref>), it remains interesting to further study the cell types that mediate the action of lovastatin. By genetically manipulating the G2019S fly model, we have shown that WGE-induced Nrf2 activation in glia but not in neurons protects dopaminergic neurons from degeneration and ameliorates impaired locomotion.</p><p>Astrocyte-like and ensheathing glia are two major types of glia in the <italic>Drosophila</italic> nervous system, surrounding and also extending long processes into neuropils of the brain. These astrocyte-like glia exhibit a morphology and function similar to those of mammalian astrocytes, including reuptake of neurotransmitters and phagocytosis of neuronal debris (<xref ref-type="bibr" rid="bib16">Freeman, 2015</xref>; <xref ref-type="bibr" rid="bib74">Tasdemir-Yilmaz and Freeman, 2014</xref>). Ensheathing glia of varying morphologies encase axonal tracts and neuropils, regulating neuronal excitability and participating in phagocytosis and injury-induced inflammation (<xref ref-type="bibr" rid="bib14">Doherty et al., 2009</xref>; <xref ref-type="bibr" rid="bib56">Otto et al., 2018</xref>). Thus, given their proximity to neurons and similar functions, it is not surprising that both types of glia collectively mediate the protective effects of WGE.</p><p>Communication between neurons and glia maintains homeostasis, yet also confers the disease state during neurodegeneration. In the <italic>Drosophila</italic> G2019S model, upregulation of the BMP ligand Gbb in dopaminergic neurons activates Mad/Smad signaling in glia, which promotes neuronal degeneration via a feedback mechanism (<xref ref-type="bibr" rid="bib49">Maksoud et al., 2019</xref>). Surprisingly, although the number of dopaminergic neurons in the fly brain is relatively small, the upregulated pMad signal spreads throughout the brain (<xref ref-type="fig" rid="fig7">Figure 7B</xref>), suggesting that BMP can be disseminated over long distances. In PD patients, higher levels of TGF-β1 have been detected in the striatum and ventricular cerebrospinal fluid (<xref ref-type="bibr" rid="bib77">Vawter et al., 1996</xref>). Thus, members of the TGF-β1 superfamily such as TGF-β1 and BMP signaling molecules may represent indicators of neuronal degeneration. Accordingly, disrupting the glia-to-neuron feedback mechanism may sustain neuronal survival. In glia, we found that WGE treatment downregulated the pMad levels that had been increased in the G2019S flies (<xref ref-type="fig" rid="fig7">Figure 7A and B</xref>). Nrf2 activation in glia also suppressed the enhanced levels of pMad in G2019S flies (<xref ref-type="fig" rid="fig8">Figure 8B and C</xref>). Indeed, our genetic assays indicate that the Nrf2 and Mad pathways interact in the glia of G2019S flies. Thus, WGE exerts its beneficial effects by activating Nrf2 to antagonize the Mad activity that would otherwise contribute to the degeneration of dopaminergic neurons. As a transcriptional activator, Nrf2 induces expression of the inhibitory component Smad7 to form inactive Smad complexes (<xref ref-type="bibr" rid="bib70">Song et al., 2019</xref>) and the phosphatase subunit PPM1A to alter Smad2/3/4 phosphorylation and DNA binding (<xref ref-type="bibr" rid="bib38">Lin et al., 2006</xref>). Given that these components are conserved in <italic>Drosophila</italic>, Nrf2 may employ similar pathways to block Mad signaling in glia.</p><p>That glial Nrf2 activation protects neurons is evidenced by our observations of enhanced HO-1 expression (<xref ref-type="fig" rid="fig4">Figure 4C</xref>) and increased numbers of dopaminergic neurons (<xref ref-type="fig" rid="fig5">Figure 5C and D</xref>). These results support that the role of Nrf2 in glia is to induce expression of antioxidation building blocks, such as phase-II detoxification enzymes, and to enhance inflammatory processes (<xref ref-type="bibr" rid="bib20">Hirrlinger and Dringen, 2010</xref>; <xref ref-type="bibr" rid="bib62">Rojo et al., 2010</xref>). In a model of fibrosis, TGF-β/Smad2/3 suppressed expression of the <italic>ARE</italic>-luciferase reporter and glutathione (<xref ref-type="bibr" rid="bib63">Ryoo et al., 2014</xref>). Moreover, Nrf2 knockdown was shown to reduce expression of the antioxidative enzyme NAD(P)H quinone dehydrogenase 1 (NQO1), thereby elevating cellular oxidative stress and upregulating TGF-β/Smad targeted gene expression (<xref ref-type="bibr" rid="bib59">Prestigiacomo and Suter-Dick, 2018</xref>). Hence, we propose that WGE promotes Nrf2 activation to antagonize the Smad signaling in glia that is induced by dopaminergic neuron-secreted BMP/Gbb signal during degeneration.</p><p>In our study, the <italic>LRRK2-G2019S</italic> mice show locomotor defects and dopaminergic loss at the age of 11.5 months. A previous study shows only earlier signs of defects, the reduction of the dopamine level and release at the age of 12 months in the <italic>LRRK2-G2019S</italic> mice (<xref ref-type="bibr" rid="bib35">Li et al., 2010</xref>), which could be contributed by the genetic background (FVB/NJ vs. C57BL/6J). Nevertheless, we have demonstrated that feeding these mice with WGE rescues their locomotor coordination, suppresses their centrophobism, and recovers their numbers of dopaminergic neurons and hyperactivated microglia (<xref ref-type="fig" rid="fig9">Figure 9</xref> and <xref ref-type="fig" rid="fig10">Figure 10</xref> A – D). Significantly, we found that the activity of the TGF-β/Smad2/3 pathway was elevated in nigrostriatal brain lysates, and this activity was also suppressed by WGE treatment (<xref ref-type="fig" rid="fig10">Figure 10</xref>). Collectively, these results from fly and mouse PD models indicate that the effectiveness of WGE is likely mediated through conserved Nrf2/Mad pathways (<xref ref-type="fig" rid="fig11">Figure 11</xref>). Our findings contribute to our mechanistic understanding of PD and provide potential therapeutic strategies that incorporate the traditional herbal medicine GE.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><sec id="s4-1"><title><italic>Drosophila</italic> stocks and maintenance</title><p>All fly stocks were maintained on standard cornmeal-based food medium at 25°C. <italic>Drosophila</italic> stocks sourced from the Bloomington <italic>Drosophila</italic> Stock Center (Indiana University, Bloomington, USA) were <italic>UAS-mCD8-GFP</italic> (#5137), <italic>elac-GAL4</italic> (#8760), <italic>repo-GAL4</italic> (#7215), <italic>Ddc-LexA</italic> (#54218), <italic>UAS-cncTRIP</italic> (#25984), <italic>Tub-GAL80<sup>ts</sup></italic> (#7108), <italic>alrm-GAL4</italic> (#67032), <italic>R56F03-GAL4</italic> (#39157), <italic>UAS-tkv<sup>Q253D</sup></italic> (#36536), and <italic>Mad<sup>K00237</sup></italic> (#10474). <italic>NP2222-GAL4</italic> (#112830) was from the <italic>Drosophila</italic> Genomics Resource Center and <italic>NP6293-GAL4</italic> (#105188) was from the Kyoto Stock Center. Other stocks include <italic>UAS-Flag-LRRK2-WT</italic> (<xref ref-type="bibr" rid="bib41">Lin et al., 2010</xref>), <italic>UAS-Flag-LRRK2-G2019S</italic> (<xref ref-type="bibr" rid="bib41">Lin et al., 2010</xref>), <italic>Ddc&gt;GAL4</italic> (<xref ref-type="bibr" rid="bib64">Sang et al., 2007</xref>), <italic>ARE-GFP</italic> (<xref ref-type="bibr" rid="bib72">Sykiotis and Bohmann, 2008</xref>), <italic>UAS-cncC-FL2</italic> (<xref ref-type="bibr" rid="bib72">Sykiotis and Bohmann, 2008</xref>), <italic>moody-GAL4</italic> (<xref ref-type="bibr" rid="bib2">Bainton et al., 2005</xref>), and <italic>UAS-Mad</italic> (<xref ref-type="bibr" rid="bib73">Takaesu et al., 2006</xref>). The two <italic>LexAop</italic> fly lines—<italic>LexAop-LRRK2-WT</italic> and <italic>LexAop-LRRK2-G2019S</italic>—were generated in this study. In brief, the cDNAs for <italic>LRRK2-WT</italic> and <italic>LRRK2-G2019S</italic> were isolated from the pDEST53-LRRK2-WT and pDEST53-LRRK2-G2019S plasmids (Addgene, MA) for subcloning into <italic>LexAop</italic> plasmids (Addgene), which were for microinjection (Fly facility, University of Cambridge, UK). The transgenes were site landed at an attP site on the 2nd chromosome (25C6). For temperature-shift assay of <italic>GAL80<sup>ts</sup></italic> flies, parental flies were maintained at 19°C and allowed to mate, before collecting the F1 adults and shifting them to 29°C to inactivate GAL80.</p></sec><sec id="s4-2"><title>Preparation of WGE and related chemical compounds</title><p>Authentication of GE and preparation of WGE were as described previously (<xref ref-type="bibr" rid="bib44">Lin et al., 2018</xref>; <xref ref-type="bibr" rid="bib42">Lin et al., 2016a</xref>). WGE (KO DA Pharmaceutical Co. Ltd., Taoyuan, Taiwan), gastrodin (Wuhan YC Fine Chemical Co., Wuhan, China), and 4-HBA (Sigma-Aldrich, Darmstadt, Germany) were added to freshly prepared cornmeal-based fly food at indicated final concentrations (w/w). For experiments, 1- to 3-day-old post-eclosion flies were collected and transferred to fresh food medium twice per week.</p></sec><sec id="s4-3"><title>Fly locomotion assay</title><p>A negative geotaxis climbing assay was performed to assess locomotor activity, and it was conducted according to a previous study with minor modification (<xref ref-type="bibr" rid="bib48">Madabattula et al., 2015</xref>). Cohorts of 35 flies from each genotype were assayed weekly for six consecutive weeks. Success rates were calculated as the percentage of flies that could climb above the 8 cm mark of a 20 cm cylinder within 10 s.</p><p>The free-walking assay protocol was conducted based on a previous report with minor modification (<xref ref-type="bibr" rid="bib9">Chen et al., 2014</xref>). Cohorts of eight flies were habituated on a 10 cm agar-filled dish for 30 min. The dishes were gently tapped to encourage the flies to walk, which was video-taped for 5 min. Movement tracks were processed in ImageJ and quantified using the Caltech multiple fly tracker (Ctrax).</p></sec><sec id="s4-4"><title>Immunostaining and immunoblotting of adult fly brains</title><p>The protocol for immunostaining whole-mount adult brains was essentially as described previously (<xref ref-type="bibr" rid="bib41">Lin et al., 2010</xref>; <xref ref-type="bibr" rid="bib49">Maksoud et al., 2019</xref>). Adult fly brains for each genotype were dissected at the indicated timepoints for immunostaining with the following primary antibodies: mouse anti-TH (Immunostar, 22941, 1:1000), mouse anti-repo (Hybridoma Bank DSHB, 8D12, 1:500), chicken anti-GFP (Abcam, ab13970, 1:10,000), and rabbit anti-phospho-Smad3 (Ser423/425) (Abcam, ab52903, 1:250) (<xref ref-type="bibr" rid="bib67">Smith et al., 2012</xref>). Fluorophore-conjugated secondary antibodies were FITC-conjugated goat anti-mouse IgG (Jackson ImmunoResearch, AB_2338589, 1:500), Alexa Fluor 488-conjugated goat anti-mouse IgG (Invitrogen, A28175, 1:500), Cy3-conjugated goat anti-mouse IgG (Jackson ImmunoResearch, AB_2338680, 1:500), Alexa Fluor 488-conjugated goat anti-rabbit IgG (Invitrogen, A27034, 1:500), and Cy5-conjugated goat anti-rat IgG (Invitrogen, A10525, 1:500). Phalloidin-TRITC (Sigma-Aldrich, P1951, 1:5000) that binds F-actin was also used for counterstaining. Immunofluorescence signals were acquired under confocal microscopy (ZEISS LSM 710, Germany).</p><p>Adult brain extracts were prepared according to a previously described protocol (<xref ref-type="bibr" rid="bib41">Lin et al., 2010</xref>). In brief, ~80 fly heads for each genotype were isolated for extract preparation. Equivalent amounts of samples (30 μg/20 μL/well) were resolved by SDS-PAGE for immunoblotting. The following primary antibodies were used: rabbit anti-human LRRK2 (Abcam, ab133474, 1:1000); rabbit anti-phospho-LRRK2 (Ser<sup>1292</sup>) (Abcam, ab203181, 1:500); rabbit anti-Akt (Cell Signaling, #4691, 1:1000); rabbit anti-<italic>Drosophila</italic> phospho-Akt Ser<sup>505</sup> (Cell Signaling, #4054, 1:500); rabbit anti-Nrf2 (Thermo Fisher Scientific, 710574, 1:1000); rabbit anti-phospho-Nrf2 (Ser<sup>40</sup>) (Thermo Fisher Scientific, PA5-67520, 1:1000); mouse anti-HO-1-1 (Thermo Fisher Scientific, MA1-112, 1:1000); rabbit anti-GAPDH (GeneTex, GTX100118, 1:5000); and rabbit anti-alpha tubulin (Cell Signaling, #2144, 1:10,000), followed by blotting with secondary antibodies peroxidase-conjugated goat anti-rabbit IgG (Jackson ImmunoResearch, AB_2307391, 1:7500) and peroxidase-conjugated goat anti-mouse IgG (Jackson ImmunoResearch, AB_10015289, 1:7500).</p></sec><sec id="s4-5"><title><italic>ARE-GFP</italic> reporter assay</title><p>The antioxidant response element (<italic>ARE)-GFP</italic> reporter assay was a modification of the protocol from a previous study (<xref ref-type="bibr" rid="bib72">Sykiotis and Bohmann, 2008</xref>). <italic>ARE-GFP</italic> flies of 1 week old (for <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1</xref>) or 6 weeks old (<xref ref-type="fig" rid="fig6">Figure 6</xref>) were fed with regular food or food containing 0.1% WGE prior to brain dissection and GFP immunostaining. To quantify <italic>ARE-GFP</italic> in the 6-week-old adult fly brain, confocal images were processed in ImageJ. Mean GFP fluorescence intensities in <italic>mCherry</italic>-labeled glial cells and TH-positive dopaminergic neurons of the PPL1 cluster were quantified and normalized as GFP/mCherry.</p></sec><sec id="s4-6"><title>Animal care and treatments</title><p>Transgenic <italic>LRRK2-G2019S</italic> mice were purchased from the Jackson Laboratory (JAX stock #009609, Bar Harbor, ME) and maintained at the animal center of the National Taiwan University Hospital (NTUH). Non-transgenic (nTg) and heterozygous transgenic <italic>LRRK2-G2019S</italic> mice were obtained by crossing heterozygous <italic>LRRK2-G2019S</italic> mice with wild-type FVB/NJ mice (JAX stock #001800). Mice at 8.5 months old were assigned to one of three groups (5–6 mice per group): nTg, <italic>LRRK2-G2019S,</italic> and <italic>LRRK2-G2019S</italic> fed with WGE (0.5 g/kg body weight per day) (<xref ref-type="bibr" rid="bib44">Lin et al., 2018</xref>) for 3 months.</p></sec><sec id="s4-7"><title>Behavioral assays</title><p>We employed two behavioral tests to assay mouse motor function, that is, an open-field assay to assess spontaneous locomotor activity and CatWalk XT gait analysis to assay coordination. Behavioral experiments were conducted blind to genotype, as described previously (<xref ref-type="bibr" rid="bib45">Lin et al., 2020</xref>).</p></sec><sec id="s4-8"><title>Immunohistochemical staining</title><p>After 3 months of WGE treatment, mice were sacrificed at the age of 11.5 months. The substantia nigra and striatum were dissected out. The substantia nigra was subjected to immunostaining, as described previously (<xref ref-type="bibr" rid="bib45">Lin et al., 2020</xref>). Anti-tyrosine hydroxylase (TH) (Millipore, AB152, 1:200) and anti-ionized calcium-binding adapter molecule 1 (Iba-1) (GeneTex, GTX100042, 1:200) were used as primary antibodies for 24 hr at 4°C. Secondary antibodies were DyLight 488 goat anti-rabbit 1:300 and Alexa Fluor 546 goat anti-rabbit at 1:200 (25°C for 1 hr). Mounting medium with DAPI (GeneTex, GTX30920) was used as a counterstain.</p></sec><sec id="s4-9"><title>Immunoblotting</title><p>Frozen nigrostriatal brain tissues were homogenized and mixed with lysis buffer to determine protein content and for immunoblotting, as described previously (<xref ref-type="bibr" rid="bib45">Lin et al., 2020</xref>). The membrane was incubated overnight at 4°C with the following primary antibodies: anti-LRRK2 (Abcam, ab133474, 1:5000), anti-phospho-LRRK2 (Ser<sup>1292</sup>, Abcam, ab203181, 1:1000), anti-Smad2 (Cell Signaling, #5339, 1:1000), anti-phospho-Smad2 (Ser465/467, Cell Signaling, #3108, 1:1000), anti-Smad3 (Cell Signaling, #9523, 1:1000), anti-phospho-Smad3 (Ser423/425, Abcam, ab52903, 1:1000), and anti-beta actin (Sigma-Aldrich, A5441, 1:5000). After washing, peroxidase-conjugated goat anti-rabbit IgG (GeneTex, GTX213110-01, 1:5000) or peroxidase-conjugated goat anti-mouse IgG (GeneTex, GTX213111-01, 1:5000) were used as secondary antibodies.</p></sec><sec id="s4-10"><title>Statistical analysis</title><p>All statistical analyses were carried out in GraphPad Prism 6 (La Jolla, CA). Data are presented as mean ± standard error (SEM). Statistical analysis was performed using either Student <italic>t</italic>-test or one-way analysis of variance (ANOVA) followed by Tukey’s multiple comparison test. p&lt;0.05 were considered indicative of significance. For exact n numbers, p-values, F-values, t-values, and degrees of freedom of each statistical test, please see the statistical information in <xref ref-type="supplementary-material" rid="sdata1">Source data 1</xref>.</p></sec></sec></body><back><sec id="s5" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn><fn fn-type="COI-statement" id="conf2"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Validation, Visualization, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con2"><p>Conceptualization, Investigation, Project administration, Resources, Supervision, Validation, Writing – review and editing</p></fn><fn fn-type="con" id="con3"><p>Data curation, Formal analysis, Methodology</p></fn><fn fn-type="con" id="con4"><p>Data curation, Formal analysis, Methodology</p></fn><fn fn-type="con" id="con5"><p>Resources</p></fn><fn fn-type="con" id="con6"><p>Resources</p></fn><fn fn-type="con" id="con7"><p>Conceptualization, Investigation, Resources, Supervision, Validation, Writing – review and editing</p></fn><fn fn-type="con" id="con8"><p>Conceptualization, Funding acquisition, Investigation, Project administration, Resources, Supervision, Validation, Writing – review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>All animal procedures were approved by the local ethics committee and the Institutional Animal Care and Use Committee (IACUC) of the National Taiwan University (IACUC approval no. 20180103).</p></fn></fn-group></sec><sec id="s6" sec-type="supplementary-material"><title>Additional files</title><supplementary-material id="transrepform"><label>Transparent reporting form</label><media mime-subtype="pdf" mimetype="application" xlink:href="elife-73753-transrepform1-v2.pdf"/></supplementary-material><supplementary-material id="sdata1"><label>Source data 1.</label><caption><title>Statistical information.</title><p>The file includes all data and the statistical analyses in this article.</p></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-73753-supp1-v2.xlsx"/></supplementary-material><supplementary-material id="sdata2"><label>Source data 2.</label><caption><title>Data—western blotting.</title><p>The file includes the uncropped images of the western blotting in this article.</p></caption><media mime-subtype="pdf" mimetype="application" xlink:href="elife-73753-supp2-v2.pdf"/></supplementary-material></sec><sec id="s7" sec-type="data-availability"><title>Data availability</title><p>All data generated or analyzed during this study are included in the manuscript and supporting files.</p></sec><ack id="ack"><title>Acknowledgements</title><p>We thank D Bohmann (URMC), U Heberlein (HHMI), SJ Newfeld (ASU), T-K Sang (NTHU), Bloomington Stock Center, <italic>Drosophila</italic> Genomics Resource Center, Kyoto Stock Center, and Taiwan Fly Core for providing fly stocks. We thank KO DA Pharmaceutical Co. Ltd. (Taoyuan, Taiwan) and Wuhan YC Fine Chemical Co. (Wuhan, China) for providing WGE and gastrodin, respectively.</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Angeles</surname><given-names>DC</given-names></name><name><surname>Gan</surname><given-names>BH</given-names></name><name><surname>Onstead</surname><given-names>L</given-names></name><name><surname>Zhao</surname><given-names>Y</given-names></name><name><surname>Lim</surname><given-names>KL</given-names></name><name><surname>Dachsel</surname><given-names>J</given-names></name><name><surname>Melrose</surname><given-names>H</given-names></name><name><surname>Farrer</surname><given-names>M</given-names></name><name><surname>Wszolek</surname><given-names>ZK</given-names></name><name><surname>Dickson</surname><given-names>DW</given-names></name><name><surname>Tan</surname><given-names>EK</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Mutations in LRRK2 increase phosphorylation of peroxiredoxin 3 exacerbating oxidative stress-induced neuronal death</article-title><source>Human Mutation</source><volume>32</volume><fpage>1390</fpage><lpage>1397</lpage><pub-id pub-id-type="doi">10.1002/humu.21582</pub-id><pub-id pub-id-type="pmid">21850687</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bainton</surname><given-names>RJ</given-names></name><name><surname>Tsai</surname><given-names>LTY</given-names></name><name><surname>Schwabe</surname><given-names>T</given-names></name><name><surname>DeSalvo</surname><given-names>M</given-names></name><name><surname>Gaul</surname><given-names>U</given-names></name><name><surname>Heberlein</surname><given-names>U</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>moody encodes two GPCRs that regulate cocaine behaviors and blood-brain barrier permeability in Drosophila</article-title><source>Cell</source><volume>123</volume><fpage>145</fpage><lpage>156</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2005.07.029</pub-id><pub-id pub-id-type="pmid">16213219</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barone</surname><given-names>MC</given-names></name><name><surname>Sykiotis</surname><given-names>GP</given-names></name><name><surname>Bohmann</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Genetic activation of Nrf2 signaling is sufficient to ameliorate neurodegenerative phenotypes in a <italic>Drosophila</italic> model of Parkinson’s disease</article-title><source>Disease Models &amp; Mechanisms</source><volume>4</volume><fpage>701</fpage><lpage>707</lpage><pub-id pub-id-type="doi">10.1242/dmm.007575</pub-id><pub-id pub-id-type="pmid">21719443</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bell</surname><given-names>KFS</given-names></name><name><surname>Al-Mubarak</surname><given-names>B</given-names></name><name><surname>Martel</surname><given-names>M-A</given-names></name><name><surname>McKay</surname><given-names>S</given-names></name><name><surname>Wheelan</surname><given-names>N</given-names></name><name><surname>Hasel</surname><given-names>P</given-names></name><name><surname>Márkus</surname><given-names>NM</given-names></name><name><surname>Baxter</surname><given-names>P</given-names></name><name><surname>Deighton</surname><given-names>RF</given-names></name><name><surname>Serio</surname><given-names>A</given-names></name><name><surname>Bilican</surname><given-names>B</given-names></name><name><surname>Chowdhry</surname><given-names>S</given-names></name><name><surname>Meakin</surname><given-names>PJ</given-names></name><name><surname>Ashford</surname><given-names>MLJ</given-names></name><name><surname>Wyllie</surname><given-names>DJA</given-names></name><name><surname>Scannevin</surname><given-names>RH</given-names></name><name><surname>Chandran</surname><given-names>S</given-names></name><name><surname>Hayes</surname><given-names>JD</given-names></name><name><surname>Hardingham</surname><given-names>GE</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Neuronal development is promoted by weakened intrinsic antioxidant defences due to epigenetic repression of Nrf2</article-title><source>Nature Communications</source><volume>6</volume><elocation-id>7066</elocation-id><pub-id pub-id-type="doi">10.1038/ncomms8066</pub-id><pub-id pub-id-type="pmid">25967870</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chatterjee</surname><given-names>N</given-names></name><name><surname>Bohmann</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>A versatile ΦC31 based reporter system for measuring AP-1 and Nrf2 signaling in <italic>Drosophila</italic> and in tissue culture</article-title><source>PLOS ONE</source><volume>7</volume><elocation-id>e34063</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0034063</pub-id><pub-id pub-id-type="pmid">22509270</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Feany</surname><given-names>MB</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Alpha-synuclein phosphorylation controls neurotoxicity and inclusion formation in a <italic>Drosophila</italic> model of Parkinson disease</article-title><source>Nature Neuroscience</source><volume>8</volume><fpage>657</fpage><lpage>663</lpage><pub-id pub-id-type="doi">10.1038/nn1443</pub-id><pub-id pub-id-type="pmid">15834418</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>PJ</given-names></name><name><surname>Sheen</surname><given-names>LY</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Gastrodiae Rhizoma (tiān má): a review of biological activity and antidepressant mechanisms</article-title><source>Journal of Traditional and Complementary Medicine</source><volume>1</volume><fpage>31</fpage><lpage>40</lpage><pub-id pub-id-type="doi">10.1016/s2225-4110(16)30054-2</pub-id><pub-id pub-id-type="pmid">24716103</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>CY</given-names></name><name><surname>Weng</surname><given-names>YH</given-names></name><name><surname>Chien</surname><given-names>KY</given-names></name><name><surname>Lin</surname><given-names>KJ</given-names></name><name><surname>Yeh</surname><given-names>TH</given-names></name><name><surname>Cheng</surname><given-names>YP</given-names></name><name><surname>Lu</surname><given-names>CS</given-names></name><name><surname>Wang</surname><given-names>HL</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>G2019S) LRRK2 activates MKK4-JNK pathway and causes degeneration of SN dopaminergic neurons in a transgenic mouse model of PD</article-title><source>Cell Death and Differentiation</source><volume>19</volume><fpage>1623</fpage><lpage>1633</lpage><pub-id pub-id-type="doi">10.1038/cdd.2012.42</pub-id><pub-id pub-id-type="pmid">22539006</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>AY</given-names></name><name><surname>Wilburn</surname><given-names>P</given-names></name><name><surname>Hao</surname><given-names>X</given-names></name><name><surname>Tully</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Walking deficits and centrophobism in an α-synuclein fly model of Parkinson’s disease</article-title><source>Genes, Brain, and Behavior</source><volume>13</volume><fpage>812</fpage><lpage>820</lpage><pub-id pub-id-type="doi">10.1111/gbb.12172</pub-id><pub-id pub-id-type="pmid">25113870</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>WC</given-names></name><name><surname>Lai</surname><given-names>YS</given-names></name><name><surname>Lin</surname><given-names>SH</given-names></name><name><surname>Lu</surname><given-names>KH</given-names></name><name><surname>Lin</surname><given-names>YE</given-names></name><name><surname>Panyod</surname><given-names>S</given-names></name><name><surname>Ho</surname><given-names>CT</given-names></name><name><surname>Sheen</surname><given-names>LY</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Anti-depressant effects of Gastrodia elata Blume and its compounds gastrodin and 4-hydroxybenzyl alcohol, via the monoaminergic system and neuronal cytoskeletal remodeling</article-title><source>Journal of Ethnopharmacology</source><volume>182</volume><fpage>190</fpage><lpage>199</lpage><pub-id pub-id-type="doi">10.1016/j.jep.2016.02.001</pub-id><pub-id pub-id-type="pmid">26899441</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chew</surname><given-names>LY</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>He</surname><given-names>J</given-names></name><name><surname>Yu</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>The Nrf2-Keap1 pathway is activated by steroid hormone signaling to govern neuronal remodeling</article-title><source>Cell Reports</source><volume>36</volume><elocation-id>109466</elocation-id><pub-id pub-id-type="doi">10.1016/j.celrep.2021.109466</pub-id><pub-id pub-id-type="pmid">34348164</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chou</surname><given-names>JS</given-names></name><name><surname>Chen</surname><given-names>CY</given-names></name><name><surname>Chen</surname><given-names>YL</given-names></name><name><surname>Weng</surname><given-names>YH</given-names></name><name><surname>Yeh</surname><given-names>TH</given-names></name><name><surname>Lu</surname><given-names>CS</given-names></name><name><surname>Chang</surname><given-names>YM</given-names></name><name><surname>Wang</surname><given-names>HL</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>G2019S) LRRK2 causes early-phase dysfunction of SNpc dopaminergic neurons and impairment of corticostriatal long-term depression in the PD transgenic mouse</article-title><source>Neurobiology of Disease</source><volume>68</volume><fpage>190</fpage><lpage>199</lpage><pub-id pub-id-type="doi">10.1016/j.nbd.2014.04.021</pub-id><pub-id pub-id-type="pmid">24830390</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clark</surname><given-names>IE</given-names></name><name><surname>Dodson</surname><given-names>MW</given-names></name><name><surname>Jiang</surname><given-names>C</given-names></name><name><surname>Cao</surname><given-names>JH</given-names></name><name><surname>Huh</surname><given-names>JR</given-names></name><name><surname>Seol</surname><given-names>JH</given-names></name><name><surname>Yoo</surname><given-names>SJ</given-names></name><name><surname>Hay</surname><given-names>BA</given-names></name><name><surname>Guo</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title><italic>Drosophila</italic> pink1 is required for mitochondrial function and interacts genetically with parkin</article-title><source>Nature</source><volume>441</volume><fpage>1162</fpage><lpage>1166</lpage><pub-id pub-id-type="doi">10.1038/nature04779</pub-id><pub-id pub-id-type="pmid">16672981</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Doherty</surname><given-names>J</given-names></name><name><surname>Logan</surname><given-names>MA</given-names></name><name><surname>Taşdemir</surname><given-names>OE</given-names></name><name><surname>Freeman</surname><given-names>MR</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Ensheathing glia function as phagocytes in the adult <italic>Drosophila</italic> brain</article-title><source>The Journal of Neuroscience</source><volume>29</volume><fpage>4768</fpage><lpage>4781</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.5951-08.2009</pub-id><pub-id pub-id-type="pmid">19369546</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fellgett</surname><given-names>A</given-names></name><name><surname>Middleton</surname><given-names>CA</given-names></name><name><surname>Munns</surname><given-names>J</given-names></name><name><surname>Ugbode</surname><given-names>C</given-names></name><name><surname>Jaciuch</surname><given-names>D</given-names></name><name><surname>Wilson</surname><given-names>LG</given-names></name><name><surname>Chawla</surname><given-names>S</given-names></name><name><surname>Elliott</surname><given-names>CJH</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Multiple Pathways of LRRK2-G2019S/Rab10 Interaction in Dopaminergic Neurons</article-title><source>Journal of Parkinson’s Disease</source><volume>11</volume><fpage>1805</fpage><lpage>1820</lpage><pub-id pub-id-type="doi">10.3233/JPD-202421</pub-id><pub-id pub-id-type="pmid">34250948</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Freeman</surname><given-names>MR</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title><italic>Drosophila</italic> Central Nervous System Glia</article-title><source>Cold Spring Harbor Perspectives in Biology</source><volume>7</volume><elocation-id>a020552</elocation-id><pub-id pub-id-type="doi">10.1101/cshperspect.a020552</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gan</surname><given-names>L</given-names></name><name><surname>Vargas</surname><given-names>MR</given-names></name><name><surname>Johnson</surname><given-names>DA</given-names></name><name><surname>Johnson</surname><given-names>JA</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Astrocyte-specific overexpression of Nrf2 delays motor pathology and synuclein aggregation throughout the CNS in the alpha-synuclein mutant (A53T) mouse model</article-title><source>The Journal of Neuroscience</source><volume>32</volume><fpage>17775</fpage><lpage>17787</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.3049-12.2012</pub-id><pub-id pub-id-type="pmid">23223297</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grotewiel</surname><given-names>MS</given-names></name><name><surname>Martin</surname><given-names>I</given-names></name><name><surname>Bhandari</surname><given-names>P</given-names></name><name><surname>Cook-Wiens</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Functional senescence in <italic>Drosophila melanogaster</italic></article-title><source>Ageing Research Reviews</source><volume>4</volume><fpage>372</fpage><lpage>397</lpage><pub-id pub-id-type="doi">10.1016/j.arr.2005.04.001</pub-id><pub-id pub-id-type="pmid">16024299</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Henry</surname><given-names>AG</given-names></name><name><surname>Aghamohammadzadeh</surname><given-names>S</given-names></name><name><surname>Samaroo</surname><given-names>H</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Mou</surname><given-names>K</given-names></name><name><surname>Needle</surname><given-names>E</given-names></name><name><surname>Hirst</surname><given-names>WD</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Pathogenic LRRK2 mutations, through increased kinase activity, produce enlarged lysosomes with reduced degradative capacity and increase ATP13A2 expression</article-title><source>Human Molecular Genetics</source><volume>24</volume><fpage>6013</fpage><lpage>6028</lpage><pub-id pub-id-type="doi">10.1093/hmg/ddv314</pub-id><pub-id pub-id-type="pmid">26251043</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hirrlinger</surname><given-names>J</given-names></name><name><surname>Dringen</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>The cytosolic redox state of astrocytes: Maintenance, regulation and functional implications for metabolite trafficking</article-title><source>Brain Research Reviews</source><volume>63</volume><fpage>177</fpage><lpage>188</lpage><pub-id pub-id-type="doi">10.1016/j.brainresrev.2009.10.003</pub-id><pub-id pub-id-type="pmid">19883686</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Houlden</surname><given-names>H</given-names></name><name><surname>Singleton</surname><given-names>AB</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>The genetics and neuropathology of Parkinson’s disease</article-title><source>Acta Neuropathologica</source><volume>124</volume><fpage>325</fpage><lpage>338</lpage><pub-id pub-id-type="doi">10.1007/s00401-012-1013-5</pub-id><pub-id pub-id-type="pmid">22806825</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jang</surname><given-names>JH</given-names></name><name><surname>Son</surname><given-names>Y</given-names></name><name><surname>Kang</surname><given-names>SS</given-names></name><name><surname>Bae</surname><given-names>CS</given-names></name><name><surname>Kim</surname><given-names>JC</given-names></name><name><surname>Kim</surname><given-names>SH</given-names></name><name><surname>Shin</surname><given-names>T</given-names></name><name><surname>Moon</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Neuropharmacological Potential of Gastrodia elata Blume and Its Components</article-title><source>Evidence-Based Complementary and Alternative Medicine</source><volume>2015</volume><elocation-id>309261</elocation-id><pub-id pub-id-type="doi">10.1155/2015/309261</pub-id><pub-id pub-id-type="pmid">26543487</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname><given-names>G</given-names></name><name><surname>Hu</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>L</given-names></name><name><surname>Cai</surname><given-names>J</given-names></name><name><surname>Peng</surname><given-names>C</given-names></name><name><surname>Li</surname><given-names>Q</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Gastrodin protects against MPP(+)-induced oxidative stress by up regulates heme oxygenase-1 expression through p38 MAPK/Nrf2 pathway in human dopaminergic cells</article-title><source>Neurochemistry International</source><volume>75</volume><fpage>79</fpage><lpage>88</lpage><pub-id pub-id-type="doi">10.1016/j.neuint.2014.06.003</pub-id><pub-id pub-id-type="pmid">24932697</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jimenez-Blasco</surname><given-names>D</given-names></name><name><surname>Santofimia-Castaño</surname><given-names>P</given-names></name><name><surname>Gonzalez</surname><given-names>A</given-names></name><name><surname>Almeida</surname><given-names>A</given-names></name><name><surname>Bolaños</surname><given-names>JP</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Astrocyte NMDA receptors’ activity sustains neuronal survival through a Cdk5-Nrf2 pathway</article-title><source>Cell Death and Differentiation</source><volume>22</volume><fpage>1877</fpage><lpage>1889</lpage><pub-id pub-id-type="doi">10.1038/cdd.2015.49</pub-id><pub-id pub-id-type="pmid">25909891</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jo</surname><given-names>K</given-names></name><name><surname>Jeon</surname><given-names>S</given-names></name><name><surname>Ahn</surname><given-names>CW</given-names></name><name><surname>Han</surname><given-names>SH</given-names></name><name><surname>Suh</surname><given-names>HJ</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Changes in <italic>Drosophila melanogaster</italic> Sleep-Wake Behavior Due to Lotus (Nelumbo nucifera) Seed and Hwang Jeong (Polygonatum sibiricum) Extracts</article-title><source>Preventive Nutrition and Food Science</source><volume>22</volume><fpage>293</fpage><lpage>299</lpage><pub-id pub-id-type="doi">10.3746/pnf.2017.22.4.293</pub-id><pub-id pub-id-type="pmid">29333381</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jucaite</surname><given-names>A</given-names></name><name><surname>Svenningsson</surname><given-names>P</given-names></name><name><surname>Rinne</surname><given-names>JO</given-names></name><name><surname>Cselényi</surname><given-names>Z</given-names></name><name><surname>Varnäs</surname><given-names>K</given-names></name><name><surname>Johnström</surname><given-names>P</given-names></name><name><surname>Amini</surname><given-names>N</given-names></name><name><surname>Kirjavainen</surname><given-names>A</given-names></name><name><surname>Helin</surname><given-names>S</given-names></name><name><surname>Minkwitz</surname><given-names>M</given-names></name><name><surname>Kugler</surname><given-names>AR</given-names></name><name><surname>Posener</surname><given-names>JA</given-names></name><name><surname>Budd</surname><given-names>S</given-names></name><name><surname>Halldin</surname><given-names>C</given-names></name><name><surname>Varrone</surname><given-names>A</given-names></name><name><surname>Farde</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Effect of the myeloperoxidase inhibitor AZD3241 on microglia: a PET study in Parkinson’s disease</article-title><source>Brain</source><volume>138</volume><fpage>2687</fpage><lpage>2700</lpage><pub-id pub-id-type="doi">10.1093/brain/awv184</pub-id><pub-id pub-id-type="pmid">26137956</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kam</surname><given-names>T-I</given-names></name><name><surname>Hinkle</surname><given-names>JT</given-names></name><name><surname>Dawson</surname><given-names>TM</given-names></name><name><surname>Dawson</surname><given-names>VL</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Microglia and astrocyte dysfunction in parkinson’s disease</article-title><source>Neurobiology of Disease</source><volume>144</volume><elocation-id>105028</elocation-id><pub-id pub-id-type="doi">10.1016/j.nbd.2020.105028</pub-id><pub-id pub-id-type="pmid">32736085</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karayel</surname><given-names>Ö</given-names></name><name><surname>Tonelli</surname><given-names>F</given-names></name><name><surname>Virreira Winter</surname><given-names>S</given-names></name><name><surname>Geyer</surname><given-names>PE</given-names></name><name><surname>Fan</surname><given-names>Y</given-names></name><name><surname>Sammler</surname><given-names>EM</given-names></name><name><surname>Alessi</surname><given-names>DR</given-names></name><name><surname>Steger</surname><given-names>M</given-names></name><name><surname>Mann</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Accurate MS-based Rab10 Phosphorylation Stoichiometry Determination as Readout for LRRK2 Activity in Parkinson’s Disease</article-title><source>Molecular &amp; Cellular Proteomics</source><volume>19</volume><fpage>1546</fpage><lpage>1560</lpage><pub-id pub-id-type="doi">10.1074/mcp.RA120.002055</pub-id><pub-id pub-id-type="pmid">32601174</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>T-H</given-names></name><name><surname>Cho</surname><given-names>K-H</given-names></name><name><surname>Jung</surname><given-names>W-S</given-names></name><name><surname>Lee</surname><given-names>MS</given-names></name><name><surname>Cookson</surname><given-names>MR</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Herbal Medicines for Parkinson’s Disease: A Systematic Review of Randomized Controlled Trials</article-title><source>PLOS ONE</source><volume>7</volume><elocation-id>e35695</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0035695</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kong</surname><given-names>EC</given-names></name><name><surname>Woo</surname><given-names>K</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Lebestky</surname><given-names>T</given-names></name><name><surname>Mayer</surname><given-names>N</given-names></name><name><surname>Sniffen</surname><given-names>MR</given-names></name><name><surname>Heberlein</surname><given-names>U</given-names></name><name><surname>Bainton</surname><given-names>RJ</given-names></name><name><surname>Hirsh</surname><given-names>J</given-names></name><name><surname>Wolf</surname><given-names>FW</given-names></name><name><surname>Frye</surname><given-names>MA</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>A Pair of Dopamine Neurons Target the D1-Like Dopamine Receptor DopR in the Central Complex to Promote Ethanol-Stimulated Locomotion in <italic>Drosophila</italic></article-title><source>PLOS ONE</source><volume>5</volume><elocation-id>e9954</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0009954</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kraft</surname><given-names>AD</given-names></name><name><surname>Johnson</surname><given-names>DA</given-names></name><name><surname>Johnson</surname><given-names>JA</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Nuclear factor E2-related factor 2-dependent antioxidant response element activation by tert-butylhydroquinone and sulforaphane occurring preferentially in astrocytes conditions neurons against oxidative insult</article-title><source>The Journal of Neuroscience</source><volume>24</volume><fpage>1101</fpage><lpage>1112</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.3817-03.2004</pub-id><pub-id pub-id-type="pmid">14762128</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kulisevsky</surname><given-names>J</given-names></name><name><surname>Pagonabarraga</surname><given-names>J</given-names></name><name><surname>Pascual-Sedano</surname><given-names>B</given-names></name><name><surname>García-Sánchez</surname><given-names>C</given-names></name><name><surname>Gironell</surname><given-names>A</given-names></name><collab>Trapecio Group Study</collab></person-group><year iso-8601-date="2008">2008</year><article-title>Prevalence and correlates of neuropsychiatric symptoms in Parkinson’s disease without dementia</article-title><source>Movement Disorders</source><volume>23</volume><fpage>1889</fpage><lpage>1896</lpage><pub-id pub-id-type="doi">10.1002/mds.22246</pub-id><pub-id pub-id-type="pmid">18709682</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kumar</surname><given-names>H</given-names></name><name><surname>Kim</surname><given-names>I-S</given-names></name><name><surname>More</surname><given-names>SV</given-names></name><name><surname>Kim</surname><given-names>B-W</given-names></name><name><surname>Bahk</surname><given-names>Y-Y</given-names></name><name><surname>Choi</surname><given-names>D-K</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Gastrodin protects apoptotic dopaminergic neurons in a toxin-induced Parkinson’s disease model</article-title><source>Evidence-Based Complementary and Alternative Medicine</source><volume>2013</volume><elocation-id>514095</elocation-id><pub-id pub-id-type="doi">10.1155/2013/514095</pub-id><pub-id pub-id-type="pmid">23533492</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lang</surname><given-names>CA</given-names></name><name><surname>Ray</surname><given-names>SS</given-names></name><name><surname>Liu</surname><given-names>M</given-names></name><name><surname>Singh</surname><given-names>AK</given-names></name><name><surname>Cuny</surname><given-names>GD</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Discovery of LRRK2 inhibitors using sequential in silico joint pharmacophore space (JPS) and ensemble docking</article-title><source>Bioorganic &amp; Medicinal Chemistry Letters</source><volume>25</volume><fpage>2713</fpage><lpage>2719</lpage><pub-id pub-id-type="doi">10.1016/j.bmcl.2015.04.027</pub-id><pub-id pub-id-type="pmid">25998502</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Patel</surname><given-names>JC</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Avshalumov</surname><given-names>MV</given-names></name><name><surname>Nicholson</surname><given-names>C</given-names></name><name><surname>Buxbaum</surname><given-names>JD</given-names></name><name><surname>Elder</surname><given-names>GA</given-names></name><name><surname>Rice</surname><given-names>ME</given-names></name><name><surname>Yue</surname><given-names>Z</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Enhanced striatal dopamine transmission and motor performance with LRRK2 overexpression in mice is eliminated by familial Parkinson’s disease mutation G2019S</article-title><source>The Journal of Neuroscience</source><volume>30</volume><fpage>1788</fpage><lpage>1797</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.5604-09.2010</pub-id><pub-id pub-id-type="pmid">20130188</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Xin</surname><given-names>P</given-names></name><name><surname>Meng</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Kuang</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>The Mechanisms of Traditional Chinese Medicine Underlying the Prevention and Treatment of Parkinson’s Disease</article-title><source>Frontiers in Pharmacology</source><volume>8</volume><elocation-id>634</elocation-id><pub-id pub-id-type="doi">10.3389/fphar.2017.00634</pub-id><pub-id pub-id-type="pmid">28970800</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>LF</given-names></name><name><surname>Doherty</surname><given-names>DH</given-names></name><name><surname>Lile</surname><given-names>JD</given-names></name><name><surname>Bektesh</surname><given-names>S</given-names></name><name><surname>Collins</surname><given-names>F</given-names></name></person-group><year iso-8601-date="1993">1993</year><article-title>GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons</article-title><source>Science</source><volume>260</volume><fpage>1130</fpage><lpage>1132</lpage><pub-id pub-id-type="doi">10.1126/science.8493557</pub-id><pub-id pub-id-type="pmid">8493557</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>X</given-names></name><name><surname>Duan</surname><given-names>X</given-names></name><name><surname>Liang</surname><given-names>YY</given-names></name><name><surname>Su</surname><given-names>Y</given-names></name><name><surname>Wrighton</surname><given-names>KH</given-names></name><name><surname>Long</surname><given-names>J</given-names></name><name><surname>Hu</surname><given-names>M</given-names></name><name><surname>Davis</surname><given-names>CM</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Brunicardi</surname><given-names>FC</given-names></name><name><surname>Shi</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>YG</given-names></name><name><surname>Meng</surname><given-names>A</given-names></name><name><surname>Feng</surname><given-names>XH</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>PPM1A functions as a Smad phosphatase to terminate TGFbeta signaling</article-title><source>Cell</source><volume>125</volume><fpage>915</fpage><lpage>928</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2006.03.044</pub-id><pub-id pub-id-type="pmid">16751101</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>LC</given-names></name><name><surname>Chen</surname><given-names>YF</given-names></name><name><surname>Tsai</surname><given-names>TR</given-names></name><name><surname>Tsai</surname><given-names>TH</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Analysis of brain distribution and biliary excretion of a nutrient supplement, gastrodin, in rat</article-title><source>Analytica Chimica Acta</source><volume>590</volume><fpage>173</fpage><lpage>179</lpage><pub-id pub-id-type="doi">10.1016/j.aca.2007.03.035</pub-id><pub-id pub-id-type="pmid">17448342</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>LC</given-names></name><name><surname>Chen</surname><given-names>YF</given-names></name><name><surname>Lee</surname><given-names>WC</given-names></name><name><surname>Wu</surname><given-names>YT</given-names></name><name><surname>Tsai</surname><given-names>TH</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Pharmacokinetics of gastrodin and its metabolite p-hydroxybenzyl alcohol in rat blood, brain and bile by microdialysis coupled to LC-MS/MS</article-title><source>Journal of Pharmaceutical and Biomedical Analysis</source><volume>48</volume><fpage>909</fpage><lpage>917</lpage><pub-id pub-id-type="doi">10.1016/j.jpba.2008.07.013</pub-id><pub-id pub-id-type="pmid">18757149</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>CH</given-names></name><name><surname>Tsai</surname><given-names>PI</given-names></name><name><surname>Wu</surname><given-names>RM</given-names></name><name><surname>Chien</surname><given-names>CT</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>LRRK2 G2019S mutation induces dendrite degeneration through mislocalization and phosphorylation of tau by recruiting autoactivated GSK3ß</article-title><source>The Journal of Neuroscience</source><volume>30</volume><fpage>13138</fpage><lpage>13149</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.1737-10.2010</pub-id><pub-id pub-id-type="pmid">20881132</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>YE</given-names></name><name><surname>Lin</surname><given-names>SH</given-names></name><name><surname>Chen</surname><given-names>WC</given-names></name><name><surname>Ho</surname><given-names>CT</given-names></name><name><surname>Lai</surname><given-names>YS</given-names></name><name><surname>Panyod</surname><given-names>S</given-names></name><name><surname>Sheen</surname><given-names>LY</given-names></name></person-group><year iso-8601-date="2016">2016a</year><article-title>Antidepressant-like effects of water extract of Gastrodia elata Blume in rats exposed to unpredictable chronic mild stress via modulation of monoamine regulatory pathways</article-title><source>Journal of Ethnopharmacology</source><volume>187</volume><fpage>57</fpage><lpage>65</lpage><pub-id pub-id-type="doi">10.1016/j.jep.2016.04.032</pub-id><pub-id pub-id-type="pmid">27109341</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>CH</given-names></name><name><surname>Lin</surname><given-names>HI</given-names></name><name><surname>Chen</surname><given-names>ML</given-names></name><name><surname>Lai</surname><given-names>TT</given-names></name><name><surname>Cao</surname><given-names>LP</given-names></name><name><surname>Farrer</surname><given-names>MJ</given-names></name><name><surname>Wu</surname><given-names>RM</given-names></name><name><surname>Chien</surname><given-names>CT</given-names></name></person-group><year iso-8601-date="2016">2016b</year><article-title>Lovastatin protects neurite degeneration in LRRK2-G2019S parkinsonism through activating the Akt/Nrf pathway and inhibiting GSK3β activity</article-title><source>Human Molecular Genetics</source><volume>25</volume><fpage>1965</fpage><lpage>1978</lpage><pub-id pub-id-type="doi">10.1093/hmg/ddw068</pub-id><pub-id pub-id-type="pmid">26931464</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>YE</given-names></name><name><surname>Chou</surname><given-names>ST</given-names></name><name><surname>Lin</surname><given-names>SH</given-names></name><name><surname>Lu</surname><given-names>KH</given-names></name><name><surname>Panyod</surname><given-names>S</given-names></name><name><surname>Lai</surname><given-names>YS</given-names></name><name><surname>Ho</surname><given-names>CT</given-names></name><name><surname>Sheen</surname><given-names>LY</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Antidepressant-like effects of water extract of Gastrodia elata Blume on neurotrophic regulation in a chronic social defeat stress model</article-title><source>Journal of Ethnopharmacology</source><volume>215</volume><fpage>132</fpage><lpage>139</lpage><pub-id pub-id-type="doi">10.1016/j.jep.2017.12.044</pub-id><pub-id pub-id-type="pmid">29288827</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>CH</given-names></name><name><surname>Tsai</surname><given-names>PI</given-names></name><name><surname>Lin</surname><given-names>HY</given-names></name><name><surname>Hattori</surname><given-names>N</given-names></name><name><surname>Funayama</surname><given-names>M</given-names></name><name><surname>Jeon</surname><given-names>B</given-names></name><name><surname>Sato</surname><given-names>K</given-names></name><name><surname>Abe</surname><given-names>K</given-names></name><name><surname>Mukai</surname><given-names>Y</given-names></name><name><surname>Takahashi</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Nishioka</surname><given-names>K</given-names></name><name><surname>Yoshino</surname><given-names>H</given-names></name><name><surname>Daida</surname><given-names>K</given-names></name><name><surname>Chen</surname><given-names>ML</given-names></name><name><surname>Cheng</surname><given-names>J</given-names></name><name><surname>Huang</surname><given-names>CY</given-names></name><name><surname>Tzeng</surname><given-names>SR</given-names></name><name><surname>Wu</surname><given-names>YS</given-names></name><name><surname>Lai</surname><given-names>HJ</given-names></name><name><surname>Tsai</surname><given-names>HH</given-names></name><name><surname>Yen</surname><given-names>RF</given-names></name><name><surname>Lee</surname><given-names>NC</given-names></name><name><surname>Lo</surname><given-names>WC</given-names></name><name><surname>Hung</surname><given-names>YC</given-names></name><name><surname>Chan</surname><given-names>CC</given-names></name><name><surname>Ke</surname><given-names>YC</given-names></name><name><surname>Chao</surname><given-names>CC</given-names></name><name><surname>Hsieh</surname><given-names>ST</given-names></name><name><surname>Farrer</surname><given-names>M</given-names></name><name><surname>Wu</surname><given-names>RM</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Mitochondrial UQCRC1 mutations cause autosomal dominant parkinsonism with polyneuropathy</article-title><source>Brain : A Journal of Neurology</source><volume>143</volume><fpage>3352</fpage><lpage>3373</lpage><pub-id pub-id-type="doi">10.1093/brain/awaa279</pub-id><pub-id pub-id-type="pmid">33141179</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Z</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Yu</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>T</given-names></name><name><surname>Jiang</surname><given-names>H</given-names></name><name><surname>Ren</surname><given-names>Q</given-names></name><name><surname>Jiao</surname><given-names>Y</given-names></name><name><surname>Sawa</surname><given-names>A</given-names></name><name><surname>Moran</surname><given-names>T</given-names></name><name><surname>Ross</surname><given-names>CA</given-names></name><name><surname>Montell</surname><given-names>C</given-names></name><name><surname>Smith</surname><given-names>WW</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>A <italic>Drosophila</italic> model for LRRK2-linked parkinsonism</article-title><source>PNAS</source><volume>105</volume><fpage>2693</fpage><lpage>2698</lpage><pub-id pub-id-type="doi">10.1073/pnas.0708452105</pub-id><pub-id pub-id-type="pmid">18258746</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luo</surname><given-names>L</given-names></name><name><surname>Kim</surname><given-names>S-W</given-names></name><name><surname>Lee</surname><given-names>H-K</given-names></name><name><surname>Kim</surname><given-names>I-D</given-names></name><name><surname>Lee</surname><given-names>H</given-names></name><name><surname>Lee</surname><given-names>J-K</given-names></name><name><surname>Arai</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Anti-oxidative effects of 4-hydroxybenzyl alcohol in astrocytes confer protective effects in autocrine and paracrine manners</article-title><source>PLOS ONE</source><volume>12</volume><elocation-id>e0177322</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0177322</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Madabattula</surname><given-names>ST</given-names></name><name><surname>Strautman</surname><given-names>JC</given-names></name><name><surname>Bysice</surname><given-names>AM</given-names></name><name><surname>O’Sullivan</surname><given-names>JA</given-names></name><name><surname>Androschuk</surname><given-names>A</given-names></name><name><surname>Rosenfelt</surname><given-names>C</given-names></name><name><surname>Doucet</surname><given-names>K</given-names></name><name><surname>Rouleau</surname><given-names>G</given-names></name><name><surname>Bolduc</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Quantitative Analysis of Climbing Defects in a <italic>Drosophila</italic> Model of Neurodegenerative Disorders</article-title><source>Journal of Visualized Experiments</source><volume>100</volume><elocation-id>e52741</elocation-id><pub-id pub-id-type="doi">10.3791/52741</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maksoud</surname><given-names>E</given-names></name><name><surname>Liao</surname><given-names>EH</given-names></name><name><surname>Haghighi</surname><given-names>AP</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>A Neuron-Glial Trans-Signaling Cascade Mediates LRRK2-Induced Neurodegeneration</article-title><source>Cell Reports</source><volume>26</volume><fpage>1774</fpage><lpage>1786</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2019.01.077</pub-id><pub-id pub-id-type="pmid">30759389</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mao</surname><given-names>Z</given-names></name><name><surname>Davis</surname><given-names>RL</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Eight different types of dopaminergic neurons innervate the <italic>Drosophila</italic> mushroom body neuropil: anatomical and physiological heterogeneity</article-title><source>Frontiers in Neural Circuits</source><volume>3</volume><elocation-id>5</elocation-id><pub-id pub-id-type="doi">10.3389/neuro.04.005.2009</pub-id><pub-id pub-id-type="pmid">19597562</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martin</surname><given-names>I</given-names></name><name><surname>Kim</surname><given-names>JW</given-names></name><name><surname>Dawson</surname><given-names>VL</given-names></name><name><surname>Dawson</surname><given-names>TM</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>LRRK2 pathobiology in Parkinson’s disease</article-title><source>Journal of Neurochemistry</source><volume>131</volume><fpage>554</fpage><lpage>565</lpage><pub-id pub-id-type="doi">10.1111/jnc.12949</pub-id><pub-id pub-id-type="pmid">25251388</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miklossy</surname><given-names>J</given-names></name><name><surname>Arai</surname><given-names>T</given-names></name><name><surname>Guo</surname><given-names>JP</given-names></name><name><surname>Klegeris</surname><given-names>A</given-names></name><name><surname>Yu</surname><given-names>S</given-names></name><name><surname>McGeer</surname><given-names>EG</given-names></name><name><surname>McGeer</surname><given-names>PL</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>LRRK2 expression in normal and pathologic human brain and in human cell lines</article-title><source>Journal of Neuropathology and Experimental Neurology</source><volume>65</volume><fpage>953</fpage><lpage>963</lpage><pub-id pub-id-type="doi">10.1097/01.jnen.0000235121.98052.54</pub-id><pub-id pub-id-type="pmid">17021400</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moehle</surname><given-names>MS</given-names></name><name><surname>Webber</surname><given-names>PJ</given-names></name><name><surname>Tse</surname><given-names>T</given-names></name><name><surname>Sukar</surname><given-names>N</given-names></name><name><surname>Standaert</surname><given-names>DG</given-names></name><name><surname>DeSilva</surname><given-names>TM</given-names></name><name><surname>Cowell</surname><given-names>RM</given-names></name><name><surname>West</surname><given-names>AB</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>LRRK2 inhibition attenuates microglial inflammatory responses</article-title><source>The Journal of Neuroscience</source><volume>32</volume><fpage>1602</fpage><lpage>1611</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.5601-11.2012</pub-id><pub-id pub-id-type="pmid">22302802</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nguyen</surname><given-names>HN</given-names></name><name><surname>Byers</surname><given-names>B</given-names></name><name><surname>Cord</surname><given-names>B</given-names></name><name><surname>Shcheglovitov</surname><given-names>A</given-names></name><name><surname>Byrne</surname><given-names>J</given-names></name><name><surname>Gujar</surname><given-names>P</given-names></name><name><surname>Kee</surname><given-names>K</given-names></name><name><surname>Schüle</surname><given-names>B</given-names></name><name><surname>Dolmetsch</surname><given-names>RE</given-names></name><name><surname>Langston</surname><given-names>W</given-names></name><name><surname>Palmer</surname><given-names>TD</given-names></name><name><surname>Pera</surname><given-names>RR</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>LRRK2 mutant iPSC-derived DA neurons demonstrate increased susceptibility to oxidative stress</article-title><source>Cell Stem Cell</source><volume>8</volume><fpage>267</fpage><lpage>280</lpage><pub-id pub-id-type="doi">10.1016/j.stem.2011.01.013</pub-id><pub-id pub-id-type="pmid">21362567</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ohta</surname><given-names>E</given-names></name><name><surname>Kawakami</surname><given-names>F</given-names></name><name><surname>Kubo</surname><given-names>M</given-names></name><name><surname>Obata</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>LRRK2 directly phosphorylates Akt1 as a possible physiological substrate: impairment of the kinase activity by Parkinson’s disease-associated mutations</article-title><source>FEBS Letters</source><volume>585</volume><fpage>2165</fpage><lpage>2170</lpage><pub-id pub-id-type="doi">10.1016/j.febslet.2011.05.044</pub-id><pub-id pub-id-type="pmid">21658387</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Otto</surname><given-names>N</given-names></name><name><surname>Marelja</surname><given-names>Z</given-names></name><name><surname>Schoofs</surname><given-names>A</given-names></name><name><surname>Kranenburg</surname><given-names>H</given-names></name><name><surname>Bittern</surname><given-names>J</given-names></name><name><surname>Yildirim</surname><given-names>K</given-names></name><name><surname>Berh</surname><given-names>D</given-names></name><name><surname>Bethke</surname><given-names>M</given-names></name><name><surname>Thomas</surname><given-names>S</given-names></name><name><surname>Rode</surname><given-names>S</given-names></name><name><surname>Risse</surname><given-names>B</given-names></name><name><surname>Jiang</surname><given-names>X</given-names></name><name><surname>Pankratz</surname><given-names>M</given-names></name><name><surname>Leimkühler</surname><given-names>S</given-names></name><name><surname>Klämbt</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>The sulfite oxidase Shopper controls neuronal activity by regulating glutamate homeostasis in <italic>Drosophila</italic> ensheathing glia</article-title><source>Nature Communications</source><volume>9</volume><elocation-id>3514</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-018-05645-z</pub-id><pub-id pub-id-type="pmid">30158546</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Panagiotakopoulou</surname><given-names>V</given-names></name><name><surname>Ivanyuk</surname><given-names>D</given-names></name><name><surname>De Cicco</surname><given-names>S</given-names></name><name><surname>Haq</surname><given-names>W</given-names></name><name><surname>Arsić</surname><given-names>A</given-names></name><name><surname>Yu</surname><given-names>C</given-names></name><name><surname>Messelodi</surname><given-names>D</given-names></name><name><surname>Oldrati</surname><given-names>M</given-names></name><name><surname>Schöndorf</surname><given-names>DC</given-names></name><name><surname>Perez</surname><given-names>M-J</given-names></name><name><surname>Cassatella</surname><given-names>RP</given-names></name><name><surname>Jakobi</surname><given-names>M</given-names></name><name><surname>Schneiderhan-Marra</surname><given-names>N</given-names></name><name><surname>Gasser</surname><given-names>T</given-names></name><name><surname>Nikić-Spiegel</surname><given-names>I</given-names></name><name><surname>Deleidi</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Interferon-γ signaling synergizes with LRRK2 in neurons and microglia derived from human induced pluripotent stem cells</article-title><source>Nature Communications</source><volume>11</volume><elocation-id>5163</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-020-18755-4</pub-id><pub-id pub-id-type="pmid">33057020</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Petridi</surname><given-names>S</given-names></name><name><surname>Middleton</surname><given-names>CA</given-names></name><name><surname>Ugbode</surname><given-names>C</given-names></name><name><surname>Fellgett</surname><given-names>A</given-names></name><name><surname>Covill</surname><given-names>L</given-names></name><name><surname>Elliott</surname><given-names>CJH</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>In Vivo Visual Screen for Dopaminergic Rab ↔ LRRK2-G2019S Interactions in <italic>Drosophila</italic> Discriminates Rab10 from Rab3</article-title><source>G3: Genes, Genomes, Genetics</source><volume>10</volume><fpage>1903</fpage><lpage>1914</lpage><pub-id pub-id-type="doi">10.1534/g3.120.401289</pub-id><pub-id pub-id-type="pmid">32321836</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prestigiacomo</surname><given-names>V</given-names></name><name><surname>Suter-Dick</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Nrf2 protects stellate cells from Smad-dependent cell activation</article-title><source>PLOS ONE</source><volume>13</volume><elocation-id>e0201044</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0201044</pub-id><pub-id pub-id-type="pmid">30028880</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Price</surname><given-names>A</given-names></name><name><surname>Manzoni</surname><given-names>C</given-names></name><name><surname>Cookson</surname><given-names>MR</given-names></name><name><surname>Lewis</surname><given-names>PA</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>The LRRK2 signalling system</article-title><source>Cell and Tissue Research</source><volume>373</volume><fpage>39</fpage><lpage>50</lpage><pub-id pub-id-type="doi">10.1007/s00441-017-2759-9</pub-id><pub-id pub-id-type="pmid">29308544</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ray Chaudhuri</surname><given-names>K</given-names></name><name><surname>Poewe</surname><given-names>W</given-names></name><name><surname>Brooks</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Motor and Nonmotor Complications of Levodopa: Phenomenology, Risk Factors, and Imaging Features</article-title><source>Movement Disorders</source><volume>33</volume><fpage>909</fpage><lpage>919</lpage><pub-id pub-id-type="doi">10.1002/mds.27386</pub-id><pub-id pub-id-type="pmid">30134055</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rojo</surname><given-names>AI</given-names></name><name><surname>Innamorato</surname><given-names>NG</given-names></name><name><surname>Martín-Moreno</surname><given-names>AM</given-names></name><name><surname>De Ceballos</surname><given-names>ML</given-names></name><name><surname>Yamamoto</surname><given-names>M</given-names></name><name><surname>Cuadrado</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Nrf2 regulates microglial dynamics and neuroinflammation in experimental Parkinson’s disease</article-title><source>Glia</source><volume>58</volume><fpage>588</fpage><lpage>598</lpage><pub-id pub-id-type="doi">10.1002/glia.20947</pub-id><pub-id pub-id-type="pmid">19908287</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ryoo</surname><given-names>I</given-names></name><name><surname>Ha</surname><given-names>H</given-names></name><name><surname>Kwak</surname><given-names>M-K</given-names></name><name><surname>Mohanraj</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Inhibitory Role of the KEAP1-NRF2 Pathway in TGFβ1-Stimulated Renal Epithelial Transition to Fibroblastic Cells: A Modulatory Effect on SMAD Signaling</article-title><source>PLOS ONE</source><volume>9</volume><elocation-id>e93265</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0093265</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sang</surname><given-names>TK</given-names></name><name><surname>Chang</surname><given-names>HY</given-names></name><name><surname>Lawless</surname><given-names>GM</given-names></name><name><surname>Ratnaparkhi</surname><given-names>A</given-names></name><name><surname>Mee</surname><given-names>L</given-names></name><name><surname>Ackerson</surname><given-names>LC</given-names></name><name><surname>Maidment</surname><given-names>NT</given-names></name><name><surname>Krantz</surname><given-names>DE</given-names></name><name><surname>Jackson</surname><given-names>GR</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>A <italic>Drosophila</italic> model of mutant human parkin-induced toxicity demonstrates selective loss of dopaminergic neurons and dependence on cellular dopamine</article-title><source>The Journal of Neuroscience</source><volume>27</volume><fpage>981</fpage><lpage>992</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.4810-06.2007</pub-id><pub-id pub-id-type="pmid">17267552</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sheng</surname><given-names>Z</given-names></name><name><surname>Zhang</surname><given-names>S</given-names></name><name><surname>Bustos</surname><given-names>D</given-names></name><name><surname>Kleinheinz</surname><given-names>T</given-names></name><name><surname>Le Pichon</surname><given-names>CE</given-names></name><name><surname>Dominguez</surname><given-names>SL</given-names></name><name><surname>Solanoy</surname><given-names>HO</given-names></name><name><surname>Drummond</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Ding</surname><given-names>X</given-names></name><name><surname>Cai</surname><given-names>F</given-names></name><name><surname>Song</surname><given-names>Q</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Yue</surname><given-names>Z</given-names></name><name><surname>van der Brug</surname><given-names>MP</given-names></name><name><surname>Burdick</surname><given-names>DJ</given-names></name><name><surname>Gunzner-Toste</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Estrada</surname><given-names>AA</given-names></name><name><surname>Sweeney</surname><given-names>ZK</given-names></name><name><surname>Scearce-Levie</surname><given-names>K</given-names></name><name><surname>Moffat</surname><given-names>JG</given-names></name><name><surname>Kirkpatrick</surname><given-names>DS</given-names></name><name><surname>Zhu</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Ser1292 autophosphorylation is an indicator of LRRK2 kinase activity and contributes to the cellular effects of PD mutations</article-title><source>Science Translational Medicine</source><volume>4</volume><elocation-id>164ra161</elocation-id><pub-id pub-id-type="doi">10.1126/scitranslmed.3004485</pub-id><pub-id pub-id-type="pmid">23241745</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Skibinski</surname><given-names>G</given-names></name><name><surname>Hwang</surname><given-names>V</given-names></name><name><surname>Ando</surname><given-names>DM</given-names></name><name><surname>Daub</surname><given-names>A</given-names></name><name><surname>Lee</surname><given-names>AK</given-names></name><name><surname>Ravisankar</surname><given-names>A</given-names></name><name><surname>Modan</surname><given-names>S</given-names></name><name><surname>Finucane</surname><given-names>MM</given-names></name><name><surname>Shaby</surname><given-names>BA</given-names></name><name><surname>Finkbeiner</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Nrf2 mitigates LRRK2- and α-synuclein-induced neurodegeneration by modulating proteostasis</article-title><source>PNAS</source><volume>114</volume><fpage>1165</fpage><lpage>1170</lpage><pub-id pub-id-type="doi">10.1073/pnas.1522872114</pub-id><pub-id pub-id-type="pmid">28028237</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>RB</given-names></name><name><surname>Machamer</surname><given-names>JB</given-names></name><name><surname>Kim</surname><given-names>NC</given-names></name><name><surname>Hays</surname><given-names>TS</given-names></name><name><surname>Marqués</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Relay of retrograde synaptogenic signals through axonal transport of BMP receptors</article-title><source>Journal of Cell Science</source><volume>125</volume><fpage>3752</fpage><lpage>3764</lpage><pub-id pub-id-type="doi">10.1242/jcs.094292</pub-id><pub-id pub-id-type="pmid">22573823</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sofroniew</surname><given-names>MV</given-names></name><name><surname>Vinters</surname><given-names>HV</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Astrocytes: biology and pathology</article-title><source>Acta Neuropathologica</source><volume>119</volume><fpage>7</fpage><lpage>35</lpage><pub-id pub-id-type="doi">10.1007/s00401-009-0619-8</pub-id><pub-id pub-id-type="pmid">20012068</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Song</surname><given-names>L</given-names></name><name><surname>He</surname><given-names>Y</given-names></name><name><surname>Ou</surname><given-names>J</given-names></name><name><surname>Zhao</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>R</given-names></name><name><surname>Cheng</surname><given-names>J</given-names></name><name><surname>Lin</surname><given-names>CH</given-names></name><name><surname>Ho</surname><given-names>MS</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Auxilin Underlies Progressive Locomotor Deficits and Dopaminergic Neuron Loss in a <italic>Drosophila</italic> Model of Parkinson’s Disease</article-title><source>Cell Reports</source><volume>18</volume><fpage>1132</fpage><lpage>1143</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2017.01.005</pub-id><pub-id pub-id-type="pmid">28147270</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Song</surname><given-names>MK</given-names></name><name><surname>Lee</surname><given-names>JH</given-names></name><name><surname>Ryoo</surname><given-names>IG</given-names></name><name><surname>Lee</surname><given-names>SH</given-names></name><name><surname>Ku</surname><given-names>SK</given-names></name><name><surname>Kwak</surname><given-names>MK</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Bardoxolone ameliorates TGF-β1-associated renal fibrosis through Nrf2/Smad7 elevation</article-title><source>Free Radical Biology &amp; Medicine</source><volume>138</volume><fpage>33</fpage><lpage>42</lpage><pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2019.04.033</pub-id><pub-id pub-id-type="pmid">31059771</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>J</given-names></name><name><surname>Xu</surname><given-names>AQ</given-names></name><name><surname>Giraud</surname><given-names>J</given-names></name><name><surname>Poppinga</surname><given-names>H</given-names></name><name><surname>Riemensperger</surname><given-names>T</given-names></name><name><surname>Fiala</surname><given-names>A</given-names></name><name><surname>Birman</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Neural Control of Startle-Induced Locomotion by the Mushroom Bodies and Associated Neurons in <italic>Drosophila</italic></article-title><source>Frontiers in Systems Neuroscience</source><volume>12</volume><elocation-id>6</elocation-id><pub-id pub-id-type="doi">10.3389/fnsys.2018.00006</pub-id><pub-id pub-id-type="pmid">29643770</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sykiotis</surname><given-names>GP</given-names></name><name><surname>Bohmann</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Keap1/Nrf2 signaling regulates oxidative stress tolerance and lifespan in <italic>Drosophila</italic></article-title><source>Developmental Cell</source><volume>14</volume><fpage>76</fpage><lpage>85</lpage><pub-id pub-id-type="doi">10.1016/j.devcel.2007.12.002</pub-id><pub-id pub-id-type="pmid">18194654</pub-id></element-citation></ref><ref id="bib73"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takaesu</surname><given-names>NT</given-names></name><name><surname>Hyman-Walsh</surname><given-names>C</given-names></name><name><surname>Ye</surname><given-names>Y</given-names></name><name><surname>Wisotzkey</surname><given-names>RG</given-names></name><name><surname>Stinchfield</surname><given-names>MJ</given-names></name><name><surname>O’connor</surname><given-names>MB</given-names></name><name><surname>Wotton</surname><given-names>D</given-names></name><name><surname>Newfeld</surname><given-names>SJ</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>dSno facilitates baboon signaling in the <italic>Drosophila</italic> brain by switching the affinity of Medea away from Mad and toward dSmad2</article-title><source>Genetics</source><volume>174</volume><fpage>1299</fpage><lpage>1313</lpage><pub-id pub-id-type="doi">10.1534/genetics.106.064956</pub-id><pub-id pub-id-type="pmid">16951053</pub-id></element-citation></ref><ref id="bib74"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tasdemir-Yilmaz</surname><given-names>OE</given-names></name><name><surname>Freeman</surname><given-names>MR</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Astrocytes engage unique molecular programs to engulf pruned neuronal debris from distinct subsets of neurons</article-title><source>Genes &amp; Development</source><volume>28</volume><fpage>20</fpage><lpage>33</lpage><pub-id pub-id-type="doi">10.1101/gad.229518.113</pub-id><pub-id pub-id-type="pmid">24361692</pub-id></element-citation></ref><ref id="bib75"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vaccaro</surname><given-names>A</given-names></name><name><surname>Issa</surname><given-names>AR</given-names></name><name><surname>Seugnet</surname><given-names>L</given-names></name><name><surname>Birman</surname><given-names>S</given-names></name><name><surname>Klarsfeld</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title><italic>Drosophila</italic> Clock Is Required in Brain Pacemaker Neurons to Prevent Premature Locomotor Aging Independently of Its Circadian Function</article-title><source>PLOS Genetics</source><volume>13</volume><elocation-id>e1006507</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pgen.1006507</pub-id><pub-id pub-id-type="pmid">28072817</pub-id></element-citation></ref><ref id="bib76"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vargas</surname><given-names>MR</given-names></name><name><surname>Johnson</surname><given-names>JA</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>The Nrf2-ARE cytoprotective pathway in astrocytes</article-title><source>Expert Reviews in Molecular Medicine</source><volume>11</volume><elocation-id>e17</elocation-id><pub-id pub-id-type="doi">10.1017/S1462399409001094</pub-id><pub-id pub-id-type="pmid">19490732</pub-id></element-citation></ref><ref id="bib77"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vawter</surname><given-names>MP</given-names></name><name><surname>Dillon-Carter</surname><given-names>O</given-names></name><name><surname>Tourtellotte</surname><given-names>WW</given-names></name><name><surname>Carvey</surname><given-names>P</given-names></name><name><surname>Freed</surname><given-names>WJ</given-names></name></person-group><year iso-8601-date="1996">1996</year><article-title>TGFbeta1 and TGFbeta2 concentrations are elevated in Parkinson’s disease in ventricular cerebrospinal fluid</article-title><source>Experimental Neurology</source><volume>142</volume><fpage>313</fpage><lpage>322</lpage><pub-id pub-id-type="doi">10.1006/exnr.1996.0200</pub-id><pub-id pub-id-type="pmid">8934562</pub-id></element-citation></ref><ref id="bib78"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>J</given-names></name><name><surname>Wu</surname><given-names>B</given-names></name><name><surname>Tang</surname><given-names>C</given-names></name><name><surname>Zhao</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Analytical Techniques and Pharmacokinetics of Gastrodia elata Blume and Its Constituents</article-title><source>Molecules</source><volume>22</volume><elocation-id>1137</elocation-id><pub-id pub-id-type="doi">10.3390/molecules22071137</pub-id></element-citation></ref><ref id="bib79"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhan</surname><given-names>HD</given-names></name><name><surname>Zhou</surname><given-names>HY</given-names></name><name><surname>Sui</surname><given-names>YP</given-names></name><name><surname>Du</surname><given-names>XL</given-names></name><name><surname>Wang</surname><given-names>WH</given-names></name><name><surname>Dai</surname><given-names>L</given-names></name><name><surname>Sui</surname><given-names>F</given-names></name><name><surname>Huo</surname><given-names>HR</given-names></name><name><surname>Jiang</surname><given-names>TL</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>The rhizome of Gastrodia elata Blume - An ethnopharmacological review</article-title><source>Journal of Ethnopharmacology</source><volume>189</volume><fpage>361</fpage><lpage>385</lpage><pub-id pub-id-type="doi">10.1016/j.jep.2016.06.057</pub-id><pub-id pub-id-type="pmid">27377337</pub-id></element-citation></ref><ref id="bib80"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>M</given-names></name><name><surname>Kang</surname><given-names>R-X</given-names></name><name><surname>Shi</surname><given-names>J-G</given-names></name><name><surname>Liu</surname><given-names>G-T</given-names></name><name><surname>Zhang</surname><given-names>J-J</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>NHBA isolated from Gastrodia elata exerts sedative and hypnotic effects in sodium pentobarbital-treated mice</article-title><source>Pharmacology, Biochemistry, and Behavior</source><volume>102</volume><fpage>450</fpage><lpage>457</lpage><pub-id pub-id-type="doi">10.1016/j.pbb.2012.06.002</pub-id><pub-id pub-id-type="pmid">22683621</pub-id></element-citation></ref></ref-list><app-group><app id="appendix-1"><title>Appendix 1</title><table-wrap id="app1keyresource" position="anchor"><label>Appendix 1—key resources table</label><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Reagent type (species) or resource</th><th align="left" valign="bottom">Designation</th><th align="left" valign="bottom">Source or reference</th><th align="left" valign="bottom">Identifiers</th><th align="left" valign="bottom">Additional information</th></tr></thead><tbody><tr><td align="left" valign="bottom">Genetic reagent (<italic>Drosophila melanogaster</italic>)</td><td align="left" valign="bottom"><italic>UAS-mCD8-GFP</italic></td><td align="left" valign="bottom">Bloomington <italic>Drosophila</italic> Stock Center</td><td align="left" valign="bottom">BDSC Cat# 5137; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:BDSC_5137">BDSC_5137</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Genetic reagent (<italic>D. melanogaster</italic>)</td><td align="left" valign="bottom"><italic>UAS-cncTRiP</italic></td><td align="left" valign="bottom">Bloomington <italic>Drosophila</italic> Stock Center</td><td align="left" valign="bottom">BDSC Cat# 25984; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:BDSC_25984">BDSC_25984</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Genetic reagent (<italic>D. melanogaster</italic>)</td><td align="left" valign="bottom"><italic>UAS-tkv<sup>Q253D</sup></italic></td><td align="left" valign="bottom">Bloomington <italic>Drosophila</italic> Stock Center</td><td align="left" valign="bottom">BDSC Cat# 36536; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:BDSC_36536">BDSC_36536</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Genetic reagent (<italic>D. melanogaster</italic>)</td><td align="left" valign="bottom"><italic>UAS-Flag-<break/>LRRK2-WT</italic></td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib41">Lin et al., 2010</xref></td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Genetic reagent (<italic>D. melanogaster</italic>)</td><td align="left" valign="bottom"><italic>UAS-Flag-<break/>LRRK2-G2019S</italic></td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib41">Lin et al., 2010</xref></td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Genetic reagent (<italic>D. melanogaster</italic>)</td><td align="left" valign="bottom"><italic>UAS-cncC-FL2</italic></td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib72">Sykiotis and Bohmann, 2008</xref></td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Genetic reagent (<italic>D. melanogaster</italic>)</td><td align="left" valign="bottom"><italic>UAS-Mad</italic></td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib73">Takaesu et al., 2006</xref></td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Genetic reagent (<italic>D. melanogaster</italic>)</td><td align="left" valign="bottom"><italic>elav-GAL4</italic></td><td align="left" valign="bottom">Bloomington <italic>Drosophila</italic> Stock Center</td><td align="left" valign="bottom">BDSC Cat# 8760; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:BDSC_8760">BDSC_8760</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Genetic reagent (<italic>D. melanogaster</italic>)</td><td align="left" valign="bottom"><italic>repo-GAL4</italic></td><td align="left" valign="bottom">Bloomington <italic>Drosophila</italic> Stock Center</td><td align="left" valign="bottom">BDSC Cat# 7215; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:BDSC_7215">BDSC_7215</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Genetic reagent (<italic>D. melanogaster</italic>)</td><td align="left" valign="bottom"><italic>alrm-GAL4</italic></td><td align="left" valign="bottom">Bloomington <italic>Drosophila</italic> Stock Center</td><td align="left" valign="bottom">BDSC Cat# 67032; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:BDSC_67032">BDSC_67032</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Genetic reagent (<italic>D. melanogaster</italic>)</td><td align="left" valign="bottom"><italic>R56F03-GAL4</italic></td><td align="left" valign="bottom">Bloomington <italic>Drosophila</italic> Stock Center</td><td align="left" valign="bottom">BDSC Cat# 39157; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:BDSC_39157">BDSC_39157</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Genetic reagent (<italic>D. melanogaster</italic>)</td><td align="left" valign="bottom"><italic>NP2222-GAL4</italic></td><td align="left" valign="bottom">Bloomington <italic>Drosophila</italic> Stock Center</td><td align="left" valign="bottom">BDSC Cat# 112830; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:BDSC_112830">BDSC_112830</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Genetic reagent (<italic>D. melanogaster</italic>)</td><td align="left" valign="bottom"><italic>NP6293-GAL4</italic></td><td align="left" valign="bottom">Kyoto Stock <break/>Center</td><td align="left" valign="bottom">DGRC Cat# 105188;RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:Kyoto">Kyoto</ext-link> Stock Center_105188</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Genetic reagent (<italic>D. melanogaster</italic>)</td><td align="left" valign="bottom"><italic>Ddc-GAL4</italic></td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib64">Sang et al., 2007</xref></td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Genetic reagent (<italic>D. melanogaster</italic>)</td><td align="left" valign="bottom"><italic>moody-GAL4</italic></td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib2">Bainton et al., 2005</xref></td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Genetic reagent (<italic>D. melanogaster</italic>)</td><td align="left" valign="bottom"><italic>Tub-GAL80<sup>ts</sup></italic></td><td align="left" valign="bottom">Bloomington <italic>Drosophila</italic> Stock Center</td><td align="left" valign="bottom">BDSC Cat# 7108; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:BDSC_7108">BDSC_7108</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Genetic reagent (<italic>D. melanogaster</italic>)</td><td align="left" valign="bottom"><italic>Ddc-LexA</italic></td><td align="left" valign="bottom">Bloomington <italic>Drosophila</italic> Stock Center</td><td align="left" valign="bottom">BDSC Cat# 54218; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:BDSC_54218">BDSC_54218</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Genetic reagent (<italic>D. melanogaster</italic>)</td><td align="left" valign="bottom"><italic>Mad<sup>K00237</sup></italic></td><td align="left" valign="bottom">Bloomington <italic>Drosophila</italic> Stock Center</td><td align="left" valign="bottom">BDSC Cat# 10474; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:BDSC_10474">BDSC_10474</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Genetic reagent (<italic>D. melanogaster</italic>)</td><td align="left" valign="bottom"><italic>ARE-GFP</italic></td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib72">Sykiotis and Bohmann, 2008</xref></td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Genetic reagent (<italic>D. melanogaster</italic>)</td><td align="left" valign="bottom"><italic>LexAop-LRRK2-WT</italic></td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom">See Materials and methods, ‘<italic>Drosophila</italic> stocks and maintenance’</td></tr><tr><td align="left" valign="bottom">Genetic reagent (<italic>D. melanogaster</italic>)</td><td align="left" valign="bottom"><italic>LexAop-LRRK2-<break/>G2019S</italic></td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom">See Materials and methods, ‘<italic>Drosophila</italic> stocks and maintenance’</td></tr><tr><td align="left" valign="bottom">Genetic reagent (<italic>Mus musculus</italic>)</td><td align="left" valign="bottom">FVB/NJ</td><td align="left" valign="bottom">The Jackson Laboratory</td><td align="left" valign="bottom">JAX stock #001800</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Genetic reagent (<italic>M. musculus</italic>)</td><td align="left" valign="bottom">FVB/N-Tg(LRRK2*<break/>G2019S)1Cjli/J</td><td align="left" valign="bottom">The Jackson Laboratory</td><td align="left" valign="bottom">JAX stock #009609</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-TH(mouse monoclonal)</td><td align="left" valign="bottom">Immunostar</td><td align="left" valign="bottom">Cat# 22941; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_572268">AB_572268</ext-link></td><td align="left" valign="bottom">IF (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-TH(rabbit polyclonal)</td><td align="left" valign="bottom">Millipore</td><td align="left" valign="bottom">Cat# AB152;RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_390204">AB_390204</ext-link></td><td align="left" valign="bottom">Mouse-IHC (1:200)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-Repo(mouse monoclonal)</td><td align="left" valign="bottom">Hybridoma Bank DSHB</td><td align="left" valign="bottom">Cat# 8D12; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_528448">AB_528448</ext-link></td><td align="left" valign="bottom">IF (1:500)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-GFP(chicken polyclonal)</td><td align="left" valign="bottom">Abcam</td><td align="left" valign="bottom">Cat# ab13970; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_300798">AB_300798</ext-link></td><td align="left" valign="bottom">IF (1:10000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-LRRK2(rabbit monoclonal)</td><td align="left" valign="bottom">Abcam</td><td align="left" valign="bottom">Cat# ab133474;RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2713963">AB_2713963</ext-link></td><td align="left" valign="bottom">Fly-WB (1:1000) mouse-WB(1:5000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-LRRK2 (phospho <break/>Ser1292)(rabbit monoclonal)</td><td align="left" valign="bottom">Abcam</td><td align="left" valign="bottom">Cat# ab203181</td><td align="left" valign="bottom">Fly-WB (1:500) mouse-WB(1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-Akt(rabbit monoclonal)</td><td align="left" valign="bottom">Cell Signaling</td><td align="left" valign="bottom">Cat# 4691;RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_915783">AB_915783</ext-link></td><td align="left" valign="bottom">WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-phospho-<italic><break/>Drosophila</italic> Akt <break/>(Ser505)(rabbit polyclonal)</td><td align="left" valign="bottom">Cell Signaling</td><td align="left" valign="bottom">Cat# 4054;RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_331414">AB_331414</ext-link></td><td align="left" valign="bottom">WB (1:500)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-Nrf2(rabbit polyclonal)</td><td align="left" valign="bottom">ThermoFisherScientific</td><td align="left" valign="bottom">Cat# 710574;RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2532742">AB_2532742</ext-link></td><td align="left" valign="bottom">WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-phospho-<break/>Nrf2 (Ser40)(rabbit polyclonal)</td><td align="left" valign="bottom">ThermoFisherScientific</td><td align="left" valign="bottom">Cat# PA5-67520;RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2691678">AB_2691678</ext-link></td><td align="left" valign="bottom">WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-HO-1-1(mouse monoclonal)</td><td align="left" valign="bottom">ThermoFisherScientific</td><td align="left" valign="bottom">Cat# MA1-112;RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2536823">AB_2536823</ext-link></td><td align="left" valign="bottom">WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-GAPDH(rabbit polyclonal)</td><td align="left" valign="bottom">GeneTex</td><td align="left" valign="bottom">Cat# GTX100118;RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_1080976">AB_1080976</ext-link></td><td align="left" valign="bottom">WB (1:5000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-alpha tubulin(rabbit polyclonal)</td><td align="left" valign="bottom">Cell Signaling</td><td align="left" valign="bottom">Cat# 2144;RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2210548">AB_2210548</ext-link></td><td align="left" valign="bottom">WB (1:10,000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-Smad2(rabbit monoclonal)</td><td align="left" valign="bottom">Cell Signaling</td><td align="left" valign="bottom">Cat# 5339;RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_10626777">AB_10626777</ext-link></td><td align="left" valign="bottom">Mouse-WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-phospho-Smad2 (Ser465/467)(rabbit monoclonal)</td><td align="left" valign="bottom">Cell Signaling</td><td align="left" valign="bottom">Cat# 3108;RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_490941">AB_490941</ext-link></td><td align="left" valign="bottom">Mouse-WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-Smad3(rabbit monoclonal)</td><td align="left" valign="bottom">Cell Signaling</td><td align="left" valign="bottom">Cat# 9523;RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2193182">AB_2193182</ext-link></td><td align="left" valign="bottom">Mouse-WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-Smad3 (phospho <break/>S423 + S425)(rabbit monoclonal)</td><td align="left" valign="bottom">Abcam</td><td align="left" valign="bottom">Cat# ab52903; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_882596">AB_882596</ext-link></td><td align="left" valign="bottom">IF (1:250) mouse-WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-beta actin(mouse monoclonal)</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">Cat# A5441;RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_476744">AB_476744</ext-link></td><td align="left" valign="bottom">Mouse-WB (1:5000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-Iba-1(rabbit polyclonal)</td><td align="left" valign="bottom">GeneTex</td><td align="left" valign="bottom">Cat# GTX100042;RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_1240434">AB_1240434</ext-link></td><td align="left" valign="bottom">Mouse-IHC (1:200)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-mouse Alexa 488(goat polyclonal)</td><td align="left" valign="bottom">Invitrogen</td><td align="left" valign="bottom">Cat# A28175;RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2536161">AB_2536161</ext-link></td><td align="left" valign="bottom">IF (1:500)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-rabbit Alexa 488(goat polyclonal)</td><td align="left" valign="bottom">Invitrogen</td><td align="left" valign="bottom">Cat# A27034;RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2536097">AB_2536097</ext-link></td><td align="left" valign="bottom">IF (1:500)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-rabbit DyLight 488(goat polyclonal)</td><td align="left" valign="bottom">ThermoFisherScientific</td><td align="left" valign="bottom">Cat# 35552;RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_844398">AB_844398</ext-link></td><td align="left" valign="bottom">Mouse-IHC (1:300)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-rabbit Alexa 546(goat polyclonal)</td><td align="left" valign="bottom">ThermoFisherScientific</td><td align="left" valign="bottom">Cat# A-11035;RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2534093">AB_2534093</ext-link></td><td align="left" valign="bottom">Mouse-IHC (1:200)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-mouse FITC(goat polyclonal)</td><td align="left" valign="bottom">Jackson ImmunoResearch</td><td align="left" valign="bottom">Cat#115-095-003;RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2338589">AB_2338589</ext-link></td><td align="left" valign="bottom">IF (1:500)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-mouse Cy3(goat polyclonal)</td><td align="left" valign="bottom">Jackson ImmunoResearch</td><td align="left" valign="bottom">Cat# 115-165-003;RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2338680">AB_2338680</ext-link></td><td align="left" valign="bottom">IF (1:500)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-rat IgG Cy5(goat polyclonal)</td><td align="left" valign="bottom">Invitrogen</td><td align="left" valign="bottom">Cat# A10525;RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2534034">AB_2534034</ext-link></td><td align="left" valign="bottom">IF (1:500)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-rabbit peroxidase(goat polyclonal)</td><td align="left" valign="bottom">Jackson ImmunoResearch</td><td align="left" valign="bottom">Cat# 111-035-144;RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2307391">AB_2307391</ext-link></td><td align="left" valign="bottom">WB (1:7500)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-mouse <break/>peroxidase <break/>(goat polyclonal)</td><td align="left" valign="bottom">Jackson ImmunoResearch</td><td align="left" valign="bottom">Cat# 115-035-003;RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_10015289">AB_10015289</ext-link></td><td align="left" valign="bottom">WB (1:7500)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-mouse <break/>peroxidase(goat polyclonal)</td><td align="left" valign="bottom">GeneTex</td><td align="left" valign="bottom">Cat# GTX213111-01;RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_10618076">AB_10618076</ext-link></td><td align="left" valign="bottom">Mouse-WB (1:5000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-rabbit peroxidase(goat polyclonal)</td><td align="left" valign="bottom">GeneTex</td><td align="left" valign="bottom">Cat# GTX213110-01;RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_10618573">AB_10618573</ext-link></td><td align="left" valign="bottom">Mouse-WB (1:5000)</td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Phalloidin-TRITC</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">Cat# P1951;RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2315148">AB_2315148</ext-link></td><td align="left" valign="bottom">IF (1:5000)</td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">WGE</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib42">Lin et al., 2016a</xref>;<xref ref-type="bibr" rid="bib44">Lin et al., 2018</xref></td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom">KO DA Pharmaceutical Co. Ltd.</td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Gastrodin</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib43">Lin et al., 2016b</xref></td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom">Wuhan YC Fine Chemical Co.</td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="char" char="hyphen" valign="bottom">4-HBA</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">Cat# H20806-10G</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent(<italic>Homo sapiens</italic>)</td><td align="left" valign="bottom">pDEST53-LRRK2-WT (plasmid)</td><td align="left" valign="bottom">Addgene</td><td align="left" valign="bottom">Addgene plasmid # 25044;RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:Addgene_25044">Addgene_25044</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent(<italic>H. sapiens</italic>)</td><td align="left" valign="bottom">pDEST53-LRRK2-G2019S (plasmid)</td><td align="left" valign="bottom">Addgene</td><td align="left" valign="bottom">Addgene plasmid # 25045; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:Addgene_25045">Addgene_25045</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent(<italic>D. melanogaster</italic>)</td><td align="left" valign="bottom">pJFRC19-13XLexAop2-IVS- myr::GFP (plasmid)</td><td align="left" valign="bottom">Addgene</td><td align="left" valign="bottom">Addgene plasmid # 26224; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:Addgene_26224">Addgene_26224</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">ImageJ</td><td align="left" valign="bottom">PMID<ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/pubmed/22930834">:22930834</ext-link></td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://imagej.nih.gov/ij">https://imagej.nih.gov/ij</ext-link>;RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_003070">SCR_003070</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">Ctrax</td><td align="left" valign="bottom">PMID<ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/pubmed/19412169">:19412169</ext-link></td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">CatWalk XT</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib45">Lin et al., 2020</xref></td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom">Noldus Information Technology</td></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">Prism 6</td><td align="left" valign="bottom">GraphPad</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_002798">SCR_002798</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">DAPI</td><td align="left" valign="bottom">GeneTex</td><td align="left" valign="bottom">Cat# GTX30920</td><td align="left" valign="bottom"/></tr></tbody></table></table-wrap></app></app-group></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.73753.sa0</article-id><title-group><article-title>Editor's evaluation</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Bellen</surname><given-names>Hugo J</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution>Baylor College of Medicine</institution><country>United States</country></aff></contrib></contrib-group><related-object id="sa0ro1" link-type="continued-by" object-id="10.1101/2021.08.25.457612" object-id-type="id" xlink:href="https://sciety.org/articles/activity/10.1101/2021.08.25.457612"/></front-stub><body><p>Your study elucidates the molecular mechanisms by which a Chinese traditional medicine compound, GE, confers neuroprotection in mouse and fly models of LRRK2 G2019S-induced Parkinson's disease and provides an avenue for a potential therapeutic treatment for patients.</p></body></sub-article><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.73753.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Bellen</surname><given-names>Hugo J</given-names></name><role>Reviewing Editor</role><aff><institution>Baylor College of Medicine</institution><country>United States</country></aff></contrib></contrib-group><contrib-group><contrib contrib-type="reviewer"><name><surname>Yu</surname><given-names>Fengwei</given-names></name><role>Reviewer</role><aff><institution>Temasek Life Sciences Laboratory</institution><country>Singapore</country></aff></contrib></contrib-group></front-stub><body><boxed-text id="box1"><p>Our editorial process produces two outputs: (i) <ext-link ext-link-type="uri" xlink:href="https://sciety.org/articles/activity/10.1101/2021.08.25.457612">public reviews</ext-link> designed to be posted alongside <ext-link ext-link-type="uri" xlink:href="https://www.biorxiv.org/content/10.1101/2021.08.25.457612v2">the preprint</ext-link> for the benefit of readers; (ii) feedback on the manuscript for the authors, including requests for revisions, shown below. We also include an acceptance summary that explains what the editors found interesting or important about the work.</p></boxed-text><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;Glial Nrf2 signaling mediates the neuroprotection exerted by <italic>Gastrodia elata</italic> Blume in Lrrk2-G2019S Parkinson's disease&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by 2 peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Suzanne Pfeffer as the Senior Editor. The following individuals involved in review of your submission have agreed to reveal their identity: Fengwei Yu (Reviewer #2).</p><p>The reviewers have discussed their reviews with one another, and the Reviewing Editor has drafted this to help you prepare a revised submission.</p><p>Essential revisions:</p><p>Please address the issues raised by the reviewers with textual changes.</p><p>Congratulations on a nice piece of compelling scientific work!</p><p><italic>Reviewer #2 (Recommendations for the authors):</italic></p><p>Can WGE treatment of 3-4-week-old G2019S flies also alleviate locomotive defects despite the onset of PD progression? If the authors have the data available, it would be nice to include in the revised version. However, this experiment is not required for the publication of the manuscript.</p><p>In a previous study by the same lab, they show that Nrf2 pathway is upregulated in neurons upon Lovastatin treatment, suggesting a neuronal function of Nrf2. Nrf2 pathway was also recently reported to regulate developmental neurodegeneration (i.e. dendrite pruning) in a cell-autonomous manner. It could be interesting to examine if Lovastatin treatment upregulates Nrf2 activity in neurons or glia in PD flies. The authors may discuss this part or investigate in their future study.</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.73753.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Reviewer #2 (Recommendations for the authors):</p><p>Can WGE treatment of 3-4-week-old G2019S flies also alleviate locomotive defects despite the onset of PD progression? If the authors have the data available, it would be nice to include in the revised version. However, this experiment is not required for the publication of the manuscript.</p></disp-quote><p>We thank the reviewer for the comment. We had investigated the therapeutic effect of WGE in the PD fly model. In the experiment, WGE feeding of <italic>Ddc&gt;G2019S</italic> flies was started on the first day of the fourth week and climbing activity was assessed at the end of the fourth week. Interestingly, 0.1% WGE is also effective to significantly improve locomotion of <italic>Ddc&gt;G2019S</italic> flies. The protective effect was reduced at week 5 and diminished at week 6 with continuation of WGE feeding. The result was included in the revised manuscript as Figure 1—figure supplement 2. We also revised the descriptions in Results (Lines: 134-140) and Figure legends of Figure 1—figure supplement 2 (Lines: 944-950) as below.</p><p>Lines: 134-140</p><p>“We also tested the WGE effect on the <italic>Ddc&gt;G2019S</italic> flies that were fed with regular food without WGE for 3 weeks. At week 4, these <italic>Ddc&gt;G2019S</italic> flies also showed a significant improvement in their climbing ability, compared to the age-matched <italic>Ddc&gt;G2019S</italic> flies fed continuously on regular food (Figure 1—figure supplement 2). The effect of improving climbing activity in the WGE-fed <italic>Ddc&gt;G2019S</italic> flies was reduced at week 5 and diminished at week 6, suggesting that WGE feeding starting at earlier stages is important for long-term locomotion improvement.”</p><p>Lines: 944-950</p><p>“Figure 1—figure supplement 2. Locomotion improvement of <italic>Ddc&gt;G2019S</italic> flies starting WGE feeding at week 4.</p><p>The climbing activities of <italic>Ddc&gt;Lrrk2</italic>, <italic>Ddc&gt;G2019S</italic>, and <italic>Ddc&gt;G2019S</italic> with 0.1% WGE feeding at week 4 were assessed at weeks 3, 4, 5 and 6. Bar graphs show success rates (mean ± SEM, N = 6) of flies climbing over 8 cm height in 10 sec. One-way ANOVA and Tukey’s post-hoc multiple comparison test were performed and statistical significance was shown as *** for <italic>p</italic> &lt; 0.001, * for <italic>p</italic> &lt; 0.05 and ns for no significance.”</p><disp-quote content-type="editor-comment"><p>In a previous study by the same lab, they show that Nrf2 pathway is upregulated in neurons upon Lovastatin treatment, suggesting a neuronal function of Nrf2. Nrf2 pathway was also recently reported to regulate developmental neurodegeneration (i.e. dendrite pruning) in a cell-autonomous manner. It could be interesting to examine if Lovastatin treatment upregulates Nrf2 activity in neurons or glia in PD flies. The authors may discuss this part or investigate in their future study.</p></disp-quote><p>We thank the reviewer for the comment. We added a paragraph to address the neuronal function of Nrf2 and lovastatin-related future works in Discussion (Lines: 437-441), as below.</p><p>Lines: 437-441</p><p>“…In a previous study, lovastatin treatment provides neuroprotection in the G2019S-induced PD model, also through the Akt/Nrf2 pathway (C. H. Lin et al., 2016). As activation of neuronal Nrf2 plays a non-conventional role in promoting developmental dendrite pruning (Chew et al., 2021), it remains interesting to further study the cell types that mediate the action of lovastatin.</p><p>Newly included references:</p><p>Chew, L. Y., Zhang, H., He, J., and Yu, F. (2021). The Nrf2-Keap1 pathway is activated by steroid hormone signaling to govern neuronal remodeling. <italic>Cell rep</italic>, <italic>36</italic>(5), 109466. https://doi.org/10.1016/j.celrep.2021.109466</p></body></sub-article></article>